System for maintaining drug information and communicating with medication delivery devices

Information

  • Patent Grant
  • 11235100
  • Patent Number
    11,235,100
  • Date Filed
    Thursday, February 16, 2017
    7 years ago
  • Date Issued
    Tuesday, February 1, 2022
    2 years ago
Abstract
A system for maintaining drug information and communicating with medication delivery devices includes software designed for use in a hospital, pharmacy or biomedical technical service environments. The software may be provided on a computer readable medium. The software allows a facility to customize a drug library with both hard and soft drug limits and other parameters for use with an infuser having a plug and play module removably inserted into a slot within a housing, or for use with an infuser having a connectivity engine enclosed within the housing. The system supports data transfer to one or more infusers connected to one or more computers. The connection between the computer and the pump can be hard wired or wireless.
Description
FIELD OF THE INVENTION

This invention relates in general to medication administration or delivery devices. More particularly, the present invention relates to a novel system for maintaining drug or medication information, providing communication between a computer and one or more infusion pumps, and assuring the integrity of such information and communication.


BACKGROUND OF THE INVENTION

Intravenous infusion therapy is prescribed where it is desirable to administer medications and other fluids directly into the circulatory system of a patient. Without alerts that warn the clinician that a higher or lower dose than clinical practice intended is being programmed, the resulting amount delivered to the patient can lead to increased morbidity or be fatal. There are various types of infusion pumps used by medical personnel to infuse medicinal fluids into a patient's body. There are very few pumps that have the feature of drug dose programming alerts. Some pumps use a customized drug library for electronically downloadable drug pumps. For example U.S. Pat. No. 6,269,340, which is incorporated by reference herein in its entirety, describes a system and computer readable medium for developing and downloading a customized drug library from a personal computer (PC) into an erasable, electronically loadable memory within the housing of a syringe pump. However, prior art systems and infusion pumps have several drawbacks. Following is a description of a novel infusion pump system that solves various problems found in the prior art.


SUMMARY OF THE INVENTION

The present invention relates to a system for communicating with one or more medication administration or delivery devices. More particularly, the invention relates to a system that utilizes a remote computer and a software program on a computer readable medium to download information to and/or upload information from one or more infusion pumps on a stand alone basis or as part of an integrated medication management system.


In one example, the software provides the remote computer with powerful drug library creation, editing, and archiving capabilities that can be used by a user, including but not limited to, a biomedical engineer, a pharmacist, a doctor, etc. A single drug formulary worksheet or database with each drug entry having an associated CCA designation can be created for the entire medical facility. The same drug may have different limits established in different clinical care areas and different device parameters and settings may be applied depending on the recommended best practices of the medical facility for a particular clinical care area. The single drug formulary worksheet is easier to control, update and maintain than a separate database or subdatabase for each clinical care area. In one example of the software, the software provides a real time rule set validator that dynamically validates entries into the drug formulary worksheet with each keystroke as the user keys in data. The user is instantly notified if a value exceeds an allowed range or if the data does not meet predetermined expected characteristics. In one example, the software also uses an extensible markup language for communications with the medication delivery devices. Communications between the computer and the devices may be validated using any desired technique(s), such as a cyclic redundancy check. In another example, a database is used to store the history of multiple infusion pumps. This enables the ability to retrieve the event log data from all pumps in one institution in one database, and being able to retrieve the data based on place of use, time, error types, etc. Other types of reports are also possible.


The software is useful, in one example, as a part of a system utilizing a computer to download information into and upload information from one or more medication delivery devices (such as infusion pumps). In one embodiment, the system includes a remote personal computer (PC) that has a memory for storing the software, a user interface, and display. The system also includes one or more infusion pumps and one or more techniques for connecting the PC to the pumps to facilitate the communication of information between the PC and the pumps. The infusion pumps can have single or multiple channels for delivering medications (i.e., fluids, medication, or mixtures thereof) to a patient. In one example, the information downloaded to the pumps can include, without limitation: a drug library with one or more drug entries typically grouped by clinical care area, drug delivery parameters (such as hard and soft limits), device settings, parameters or limits; patient specific information such as patient identification data; and caregiver specific information such as caregiver identification.


In one example, the software and the communication protocol utilize an open architecture that is adaptable to different versions, models and makes of medication delivery devices. In one embodiment of the present invention, the software is utilized in a system that establishes wired communication with a plurality of general purpose infusion pumps for downloading and uploading information. In other embodiments, the software is utilized in a system that establishes wireless communication with one or more general purpose infusion pumps having plug and play communication modules installed within the pump housing for downloading and uploading information. In other embodiments the plug and play communication module is integrally incorporated on an optional circuit board enclosed within the pump housing. Examples of medication delivery devices included, but are not limited to, single or multiple channel general purpose infusion pumps, patient controlled analgesia (PCA) pumps, ambulatory pumps, enteral pumps, IV infusion pumps, etc.


The software is also useful on a computer that interfaces with or acts as a medication management unit or server. In this example, the software facilitates communication between the PC and one or more medication delivery devices within a patient area network (PAN). Examples of what the communication between the PC and devices can be used for include, but are not limited to, downloading patient specific drug delivery instructions for operating and controlling the medication delivery device, and uploading information such as device characteristics, conditions, usage and alarm histories.





BRIEF DESCRIPTION OF THE DRAWINGS

The present invention is illustrated by way of example and not limitation in the figures of the accompanying drawings, in which like references indicate similar elements.



FIG. 1 is a front view of an infusion pump according to the present invention.



FIG. 1A is a rear view of the infusion pump of FIG. 1.



FIG. 1B is a rear perspective view of the infusion pump of FIG. 1 and shows the plug and play module that facilitates communication between the pump and the computer.



FIG. 1C is a front perspective view of a CD-ROM disk or one possible embodiment of a computer readable medium according to the present invention.



FIG. 1D is a perspective view of a data cable which can be used to bring multiple pumps into communication with the computer through connection to a junction box.



FIG. 1E is a perspective view of a dual jacked junction box cable for connecting the pump plug and play module to the computer and interconnecting to other pumps.



FIG. 1F is a perspective view of a data cable for connecting the computer to one of the dual jacks on the junction box.



FIG. 2 is a diagram illustrating how the present invention may be used.



FIG. 3 is a diagram illustrating one example of a process for customizing a library.



FIG. 4 is a diagram illustrating the communication between the PC and infusion pumps.



FIG. 4A is a flow diagram illustrating the process of editing and downloading a drug library.



FIG. 5 is a rear view depicting the connection of a plurality of pumps to the computer.



FIG. 6 is an example of a worksheet the pharmacist sees on the computer with the present invention.



FIG. 7 shows an example of a soft limit override report.



FIG. 7A is a table explaining the report of FIG. 7.



FIGS. 7B-7E and 8A-D show examples of a soft and hard limit override reports for several different drugs.



FIGS. 9-11 are block diagrams of exemplary connectivity that may be used with the present invention.



FIGS. 12A-14 are block diagrams of one example of an electronics system for use with the present invention.



FIG. 15 is a diagram showing an example of a dialog box used when editing a rule set for a drug.



FIG. 15A is a table showing the valid entry ranges for various fields or values in the Rule Set Editor of the present invention.



FIG. 16 shows one example of a rule set validator decision tree.



FIG. 17-19 are block diagrams showing a patient controlled analgesia pump with a wireless connectivity or communication engine according to the present invention.



FIG. 20 is a diagram of one example of the XML exchange schema.



FIG. 20A is a table showing the XML object tag names utilized in one example of the present invention.



FIG. 21 is an example of a dialog box used with the rule set editor when adding, editing, deleting, or viewing a rule set.



FIG. 22 is a block diagram illustrating the relationship between a DataModel and DataItem.



FIGS. 23-25 are diagrams illustrating the high-level interactions between various processes of the present invention.



FIG. 26 is a diagram illustrates a data model to support a soft limit alert or override clinical event.





DETAILED DESCRIPTION

In general, the present invention provides a system and method for providing communication between a computer and one or more medication administering devices. The invention uses hardware and software to provide the link between the computer and the infusion pumps. In one example, the invention is designed for use in a pharmacy or biomedical technical service environment or in a Medication Management Unit (MMU) as described in applicant's co-pending provisional application Ser. No. 60/527,583 entitled MEDICATION MANAGEMENT SYSTEM, filed Dec. 5, 2003 and the regular patent application by the same title, filed Feb. 20, 2004, which are expressly incorporated herein in their entirety.


The invention allows a facility to customize a drug library for use with an infusion pump, such as a PLUM A+® infuser or pump, available from Abbott Laboratories in Abbott Park, Ill. Other types of pumps may also be used with the present invention. For example, the invention may be used with patient-controlled analgesia (PCA) pumps, ambulatory pumps, enteral pumps, as well as IV infusion pumps. The invention also provides for storage of data from multiple pumps and generates various safety reports, events and alarm reports.



FIG. 1 is a front view of an Abbott PLUM A+® infuser or pump 12. FIG. 1A is a rear view of the PLUM A+® pump of FIG. 1 wherein the housing 2 has been modified to include a vertically elongated slot 3 formed therein for receiving a plug and play module 4 inside the housing 2 to facilitate the communication between the computer and the infusion pumps. The plug and play module 4 is operatively disposed inside the housing 2 and substantially enclosed, protected and insulated by the housing. The plug and play module 4 has a thin, elongated card-shaped case that fit into the slot 3 of the pump housing 2. Thus, the plug and play module 4 of the present invention does not substantially increase the space occupied by the pump. The plug and play module 4 shown in FIGS. 1A and 1B is adapted for hard-wired communication. However, as discussed below, the plug and play module 4 can also be adapted for wireless communication.


In one example, software of the present invention can store up to twelve Clinical Care Areas (CCAs) with up to 100 drug entries (99 drug entries and No Drug Selected) in each CCA for a total of 1200 entries in the Master Drug Formulary. In this example, the software of the present invention supports data transfer of up to fifteen Abbott PLUM A+® Single-Channel Infusers connected to a single computer. Of course, the invention can be designed with different storage and communication capabilities and be adapted for different pumps.



FIG. 2 is a diagram illustrating how the present invention may be used. As shown in FIG. 2, once the software is installed on a host computer (in this example, a personal computer or PC 10), a user can create a drug library (or use a library provided with the software media), including any desired rule sets. The drug library may include entries including drug name, drug amount, drug unit, diluent amount, diluent units, dosing units, drug class, hard limits and soft limits within the hard limits. It is not necessary to enter the drug concentration because this value is derivable from the drug amount, drug unit, diluent amount and diluent units. A user may also create a plurality of CCAs within the library. Next, the user can connect the PC to a plurality of infusers 12 and begin data transfer between the PC and the infusers. For example, the active drug library can be downloaded from the PC to the connected infusers. In addition, data can also be transferred from the infuser to the PC. For example, event and alarm logs can be uploaded from connected infusers to the PC. Any other desired type of data or communications can also be transferred between the PC and infusers.



FIG. 3 is a diagram illustrating one example of a process for customizing a library. The process of FIG. 3 begins with a user, such as a pharmacist, creating a worksheet on a PC 10. In this example, a worksheet can be thought of as a library that can still be edited and has not yet been finalized. One salient feature of the worksheet is that it provides two simultaneous views: a target “working” formulary view and a source “reference” formulary view. In one example, a master formulary view of the drugs can be in the reference view, while at the same time, a view of target drugs for the CCA is shown. Likewise, in another example, the target view could be one CCA such as “Medical” while the source is another CCA such as “Surgery”. The pharmacist is able to copy the exact same drug entry with its associated rule sets from the source to the target. This presentation reduces the time it takes to develop all the necessary CCAs and promotes easy quality checks for the pharmacist and a view across all the drug rule sets being developed. In addition there is a reduction in typing errors if one was forced to reenter the same drug name, concentration and rule sets in numerous different CCAs. Errors in developing a drug library can lead to a reduced safety net for the nurses and increased patient morbidity. FIG. 6 shows one example of a worksheet that a pharmacist (or other user) may see on a computer with the present invention. FIG. 6 shows a split screen view, with a master drug formulary table on the bottom portion 14 of the screen, and the drugs in the selected CCA on the top portion 16 of the screen. A pull down menu 18 is used to select which CCA is viewed in the top portion 16.


Referring to FIGS. 3 and 20, the user next creates a CCA (if one is not already created), which is a subset of a drug library for use in an area or patient population of the hospital (e.g., Intensive Care Unit (ICU)), as defined by an authorized user. Each CCA can have a predefined number of specific drugs. Also, a hospital can have a plurality of CCAs in a drug library. Next, the user creates any desired drug classes (for example, antibiotics, narcotics, beta blockers, etc.) and then adds drug entries with rule sets to CCAs. Next, the CCA infuser settings are set. Examples of CCA infuser settings include maximum rate, default occlusion pressure, and maximum and/or minimum patient weight. Next, master infuser settings are set up. Examples of master infusion settings include Continue Rate (the default rate the infuser switches to after a therapy has completed), Enable Delay/Standby (the default stand by setting), Callback Notification (when enabled, causes the infuser 12 to emit an audible nurse callback alarm and display a notification between steps during a multi-step infusion or after loading a dose), and Deliver Together (allows you to choose as a default the 2-channel delivery method). Before finalizing the worksheet, a worksheet report can be printed and reviewed. Finally, the worksheet is finalized as the active library.


After an active library is ready, a technician can connect one or more infusers 12 to the PC 10 for data transfer. FIGS. 4 and 5 are diagrams illustrating the communication between the PC 10 and the infusers 12. First, the active library is imported. Next, the technician connects the infusers 12 to the PC 10. The infusers 12 can be connected to the PC 10 in any desired manner. For example, a cable (FIG. 1F) can be connected between a serial port on the PC 10 and a junction box (FIG. 1E), which is also connected to the data port of each infuser 12 through the plug and play module 4 (FIG. 1A). The infusers 12 and PCs 10 can use any desired type of interfaces including serial interfaces (RS232, USB, etc.), parallel interfaces, etc. In another example, the infusers 12 can have wireless capabilities to provide a connection to the PC 10 as needed. Once connected, information including but not limited to programming events, settings, and alarms, etc. can be uploaded to the PC as historical information (logs) or real-time information, and the active library can be downloaded to all of the infusers 12. FIG. 5 is a diagram illustrating the connection of a plurality of pumps to a computer using a serial cable with a plurality of serial connectors and a plurality of junction boxes.



FIG. 4A is another flow diagram illustrating the process described above. As shown, a hospital formulary can be imported into one or more worksheets. After a user finalizes a drug library, the active drug library can be downloaded to one or more infusers. FIG. 4A also illustrates that drug libraries can be archived and used again when developing or editing worksheets.


The present invention includes several features that solve various problems in the prior art. Following is a description of these features.


The present invention makes use of Extensible Markup Language (XML) representation for Remote Procedure Calls (RPC). One benefit of using XML is that the use of XML syntax documents allows the protocol to support different types of products. For example, a first infuser may only allow a certain communication format that is different from that required by another infuser. By using XML, the system can communicate with different types of infusers. Examples of different types of devices include devices with different computer architectures, devices running different types of computer processors, devices running different software programs (or different versions of the same program). In addition, some devices operate using a binary data format that may be incompatible with the binary format used on other devices. In this way, the host computer can use the same message formats for various different types of devices. The invention also provides the use of an XML parser in communicating with a patient-connected medical device, such as an infusion pump.


In some applications of the present invention, the host and the pump may have incompatible binary data formats. For this reason, it is necessary to define a lexical form that is the same on the host and the pump. This common lexical representation is called the canonical form. The process of converting from the processor-specific binary form to the canonical form is called canonicalization.


Error checking commonly uses checksum or hash functions. However, these functions are not always reliable. Since the present invention uses medically critical data, it is important to use a more reliable error checking function. In addition, it is desirable to allow partial library updates (such as an individual item in the drug library), while still being able to validate the content of the entire library. The present invention supplements standard checksum or hash function with a Global Canonical Cyclic Redundancy Check (gCCRC) which guards the state of the entire exchange data structure. Its purpose is to allow the host and pump to verify that their data is the same after attempted data transmission. The gCCRC can detect errors that are not trapped by lower level checksum and other methods. For example, the gCCRC can detect when the number of packets dropped is exactly the range of sequence numbers. The gCCRC also provides a final “backstop” validation against every sort of protocol failure, including exceptions like pump disconnection, power failure, and software defects.


In one example, rather than the conventional approach of comparing two binary images (an image at the host computer and an image at the infuser) to see if they are the same to validate the content of data stored in the infuser, a comparison is made to determine whether two possibly entirely different physical (bit-wise) representations are semantically the same. This is accomplished by using a canonical representation (which neither side actually uses for storage) and then doing the comparison between the two abstract representations. For example, to validate the contents of data in the infusion pump, a CRC is calculated based on the data in the pump. Next, a CRC is calculated based on what the host thinks the data in the pump is. Next, these numbers are compared. If the numbers are the same, it is highly likely that the data is the same at the host and at the infuser. One advantage to this approach is that only a small amount of data is required to be transferred for comparison purposes. A binary image of the entire library does not need to be retransmitted for comparison. This approach also eliminates the requirement of error checking during data transmission.


Another aspect of the present invention relates to how the CRC is calculated. The form of CRC used is specified by the Comite Consultatif Internationale de Telegraphique et Telephonique (CCIT). However, with the present invention, the CCIT CRC is done in the opposite bit order (right to left, versus left to right as specified by CCIT) so as to make the computation more efficient. It turns out that since Intel processors have the opposite “endianness” from the so-called “network byte order” prescribed by the CCIT, the bit reversal avoids some implementation problems on some processors.


When constructing the words (which may have different endianness) described above using CRC, it is important to precisely define the syntax of the document or data before using CRC. The present invention uses XML schema for this purpose. In addition, XML schema is used to define the semantics used for validation). The data to be validated (e.g., a drug library) is converted to its canonical form (described above) and validated and verified using the XML schema to determine whether the data is both valid and well formed. In the example of a library, this validation check occurs before transmitting the library to the pump.


One example of the XML schema of the present invention includes two main parts, exchange schema and implied schema. Generally, the exchange schema defines the structure of data to be communicated between a host computer and an infusion pump. The implied schema defines (and validates) the types of data being exchanged.



FIG. 20 is a diagram showing one example of the XML exchange schema, using unified modeling language (UML) notation. As shown in the example of FIG. 20, a drug library includes infuser settings, at least one drug entry, and active library objects. In this example, there is only one infuser settings object and one active library object, but up to 1200 drug entry objects. Each object shown in FIG. 20 contains attributes as described in its respective box. The active library object includes up to 12 CCA objects. Each CCA object includes up to 100 rule set objects. In this example, there is only one rule set per drug, although multiple drugs can share a single rule set. The data structures shown in FIG. 20, and their members, are defined as an XML object with tag names (which are optionally abbreviated/compacted) for each entry. FIG. 20A identifies the names used in one example. FIG. 20A shows commands along with queries and responses, and their corresponding abbreviations. As shown, in addition to the data structures, the commands and queries are also encoded in XML, and are processed the same as data by the host computer (or server) and pump (or client) sides. As is apparent to one skilled in the art, the commands and queries can be used with the present invention to efficiently provide communication between a host computer and a client infusion pump. For example, the following command ends drug library updates, while communicating the server's calculated global canonical checksum to the client (<xEU gccrc=“9B8D”/>). As shown in FIG. 20A, “xEU” is the abbreviation for the command “EndLibraryUpdate”, while the value “9B8D” is an example of a hexadecimal value of the server's checksum. The other commands and queries are used in a similar manner.


The implied data is a contract between the host computer 10 and the infusion pump 12. The implied data is managed by the host and used when developing software for the host and clients. In one example, the implied data is not transmitted over the communications link, nor does the infuser software ever process it. One purpose of the implied schema is to validate the value and types of data that are allowed to be passed to the client. One form of validation is range checking to restrict out of range values from being transmitted. Another form of validation can be display accuracy. For example, the display range of a variable can be tenths of digit. In such cases, sending a value of 12.00 would be invalid as it describes accuracy beyond the range of the variable. Another type of validation may be specific type checking. The implied schema takes the form of an XML schema document. The XML schema document provides type definitions for all the client/host specific type definitions in the exchange schema. The following are examples of various implied schema types. The first example is a simple string type schema, which defines an institution name string to be 30 characters or less.

















<?xml version=″1.0″ encoding=″UTF-8″?>




<xs:schema xmlns:xs=″http://www.w3.org/2001/XMLSchema″>




 <!-- defines t_InstitutionName as a 30-character string -->




 <xs:simpleType name=”t_InstitutionName”>




  <xs:restriction base=”xs:string”>




   <xs:maxLength value=”30”/>




  </xs:restriction>




 </xs:simpleType>




</xs:schema>









XML schema supports fixed-point representations directly through a fractionDigits facet on most numeric data types. The following examples define minimum and maximum decimal and fraction digit values.




















A fixed point type specification





<xs:simpleType name = ”t_DefaultVTBI”>





   <xs:restriction base = ”xs:decimal”>





    <xs:minInclusive value = ”0.1”/>





    <xs:maxInclusive value = ”999.0”/>





    <xs:fractionDigits value = ”1”/>





  </xs:restriction>





 </xs:simpleType>










In one example, the present invention constructs an implied enumeration by defining an xs:enumeration restriction over an EncodedString.




















A MESA implied enumeration t_DosingUnits





<xs:simpleType name=”t_DosingUnits”>





 <xs:restriction base=“EncodedString”>





  <xs:enumeration value=”mL/hr” encoding=”0”/>





  <xs:enumeration value=”mcg/kg/min” encoding=”1”/>





  <xs:enumeration value=”mcg/kg/hr” encoding=”2”/>





  <xs:enumeration value=”mcg/min” encoding=”3”/>





  <xs:enumeration value=”mcg/hr” encoding=”4”/>





  <xs:enumeration value=”mg/kg/hr” encoding=”5”/>





  <xs:enumeration value=”mg/min” encoding=”6”/>





  <xs:enumeration value=“mg/hr” encoding=”7”/>





  <xs:enumeration value=“grams/hr” encoding=”8”/>





  <xs:enumeration value=”ng/kg/min” encoding=”9”/>





  <xs:enumeration value=”units/kg/hr” encoding=”10”/>





  <xs:enumeration value=”units/min” encoding=”11”/>





  <xs:enumeration value=”units/hr” encoding=”12”/>





  <xs:enumeration value=”mUn/min” encoding=”13”/>





  <xs:enumeration value=”mEq/hr” encoding=”14”/>





 </xs:restriction>










Multiple ranges for a single value can be specified for a value via the <xs:choice> tag. The following examples relate to a patient weight field, including upper and a lower ranges.


t_PatientWeight
















<xs:group name=”t_PatientWeight”>



 <xs:choice>



  <xs:element name=”PatientWeight” type=”t_PatientWeight_0”/>



  <xs:element name=”PatientWeight” type=”t_PatientWeight_1”/>



 </xs:choice>



</xs:group>









t_PatientWeight_0



















<xs:simpleType name = ”t_PatientWeight_0”>




 <xs:restriction base = ”xs:decimal”>




  <xs:minInclusive value = ”100”/>




  <xs:maxInclusive value = ”500”/>




  <xs:fractionDigits value = ”0”/>




 </xs:restriction>




</xs:simpleType>










t_PatientWeight_1




















<xs:simpleType name = ”t_PatientWeight_1”>





  <xs:restriction base = ”xs:decimal”>





   <xs:minInclusive value = ”0.1”/>





   <xs:maxInclusive value = ”99.9”/>





   <xs:fractionDigits value = ”1”/>





 </xs:restriction>










One issue with using XML is that XML is very verbose, which increases bandwidth requirements. To reduce communications overhead, the invention uses a more compact form of XML that is still standard compliant, but operates with significantly reduced bandwidth by abbreviating the XML identifiers to a few character mnemonics. The encoding is well formed XML that uses terse element and attribute names. In one example, each XML Short Name may consist solely of alphabetic characters and be uniquely identified by its first character. The commands pass arguments as XML attributes. The responses return values as attribute values and/or as elements nested inside the response element. For example, the long XML name “InfuserSetting” is shortened to “IS”. So, an exemplary line of commands might look like this:


Example: Compact PumpConfiguration Instance



















<IS>





 <FKR>1</FKR>





 <LPB>0</LPB>





 <iDS>true</iDS>





 <dCB>true</dCB>





 <HXP>6</HXP>





</IS>











rather than the non-compact version, which would look like this:


Example: PumpConfiguration Instance















<InfuserSetting>



 <KVORateMode>KVO</KVORateMode>



 <PiggybackMode>CONCURRENT</PiggybackMode>



 <DelayStart>true</DelayStart>



 <Callback>true</Callback>



 <DefaultOcclusionPressure>6</DefaultOcclusionPressure>



</InfuserSettings>









In this example, the encoding reduced approximately 200 characters to approximately 60 characters, yielding a ratio of about 3.3 to 1.


The present invention uses an extended data port protocol that includes a reliable binary transport protocol on top of the data port protocol. In other words, a protocol is run over the data port protocol. One advantage of this approach is improved compatibility between different machines. Another advantage is that large messages can be segmented and reassembled. This allows very large messages to be sent through the protocol stack, even if the host or pump cannot handle large messages. A large message will be segmented into small packets and later reassembled.


The invention assures the safety of the database by allowing only one library to be maintained in the computer that can be downloaded to pumps and is termed the active library. This assures that the wrong library is not downloaded over time. A library that can be edited is termed a worksheet and many different worksheets can exist. A library that was once active and is no longer active is archived and automatically designated as such. To be able transfer an active library to another computer a unique special file extension and recognition was developed. This allows for the transfer of the exact same library between pharmacies of a larger health care facility that may have multiple sites.


Another advantage of the present invention is that the system is capable of simultaneously downloading data to a plurality of infusion pumps. The library is transmitted in a multicast fashion to multiple pumps. The system will periodically verify the status of each pump using point to point communication. If one of the pumps has a problem, the download can be restarted, and each pump will be notified of the new download. In one example, when a pump detects a download error during a broadcast download, the pump sends a message to the host computer, which then halts the download. The host then polls all of the pumps to determine the point where all of the pumps received messages with valid data. Since the download takes place over multiple individual tagged messages, a tag number allows the host computer to identify the point where no pumps had reported a download error. When the download is continued, the download begins at this point, so all of the data does not have be downloaded again. The multicast communication strategy optimizes the download throughput. For example, if a library takes 10 minutes to download, 15 pumps can received the download in 10 minutes, as opposed to the 150 minutes it would take to download to each pump individually. This blend of multicast and point-to-point communication facilitates a robust download and a retry/recovery mechanism to individual pumps. Another advantage of the current invention is that the worksheet provides the pharmacists with a master formulary view at the same time providing for a CCA view of drug entries. Editing and copying of drug entries can be done in either view. This presentation promotes easy quality checks, a safety feature, for the pharmacist as drug or dosing limit alerts being developed. Errors in developing a drug library can lead to a reduced safety net for the nurses and increased patient morbidity.


Another advantage of the present invention is that a single database can be used to store the history of multiple infusion pumps. This enables the ability to retrieve the event log data from all pumps in one institution in one database, and being able to retrieve the data based on place of use, time, error types, etc. Other types of reports are also possible. Also, even with a centralized database, the system can include multiple PCs, which can each download to any desired pumps.


Similarly, the present invention is capable of collecting pump use data and generating related reports. For example, soft limit override data can be collected for the generation of a report relating to soft limit overrides. This type of report can be used for any desired purpose such as evaluating personnel, setting future limits, etc.


The present invention includes an active drug library editor that can validate drug data in real time. The invention is capable of managing an unlimited number of drug libraries. Drug libraries are configured with a Master Drug Formulary (the drug table from which CCAs are created) and multiple CCAs. Libraries can be active (a worksheet that has been finalized), archived (a previously active library that has been saved to the database) or a worksheet (a draft library that has not yet been approved for download to infusers and can still be edited). Only active libraries are allowed to be downloaded to a pump. Items such as configuration parameters that describe the operational behavior of a pump can be set pump-wide or specific to a CCA. These parameters are unique to each library. TallMan lettering is supported for drug names. Changes to TallMan lettering is replicated throughout a library. Each drug in the library is associated with a drug classification. Drug classifications are unique to each library. A drug may have multiple concentrations and multiple rule sets. Rule sets can be full, limited, or none.


Another feature of the present invention relates to the various levels of rules that the active drug library can utilize. The present invention allows the use of multiple rule levels including device rules (e.g., rules relating to the operation or limitations of a particular medical device or type of device), CCA rules (e.g., rules relating to the particular CCA), drug rules (rules relating to the particular drugs), and patient rules (e.g., rules relating to particular patients such as age, weight, health, medical history, allergies, etc.).


The Rule Set Editor (RSE) is used to create and edit rules sets in a drug database. RSE is responsible for accurately displaying rule sets and enabling the “Add”, “Save” or “Delete” buttons when appropriate. FIG. 21 shows an example of a dialog box used with the RSE when adding, editing, deleting, or viewing a rule set. As shown in FIG. 21, there are fields for drug name, drug class, drug amount, drug diluent, and soft/hard limits. RSE is responsible for adjusting its input criteria and validating a rule set while a user is making input selections. RSE uses RuleSetDataItem (RSDI) (described below) as a data model and RuleSetValidator (RSV) (described below) as a controller. RSE sends a message to RSDI when the model should be validated. RSDI, in turn, sends a message to RSV to validate RSDI. This separation of responsibility is established to encapsulate a standard validation implementation for both the rule set editor user interface and the library import process.


Another advantage of the present invention relates to the drug configuration. The present invention includes a special rule set that allows the definition of a drug name and concentration for a particular drug. However, at the pump, a user can override the drug amount and drug unit. So, a limit is set, but a user is allowed to define the concentration. Therefore, the invention has the ability to selectively limit or allow the user to select the units of delivery on a drug-by-drug basis, and the ability to label a drug with concentration in drug units, but deliver in other units (such as ml/hr).


Another advantage of the present invention relates to constraint definitions. The invention includes a set of unique constraint objects. A constraint object defines a standard implementation for validating keyboard, mouse and import inputs. For example, a particular field may be constrained to a numerical range. The constraints prevent things from being done incorrectly. However, sometimes one object input is based on the content of another object and with the present invention constraint definitions change dynamically as input definitions change. For example, for the object “drug amount”, the constraint can change depending on the units of measure (e.g., grams, etc.).


Dose Rate Document (DRD) aggregates multiple constraints so that input verification can be cascaded through an unlimited number of constraint objects. In one example of an implementation of a DRD, the object DoseRateDocument extends javax.swing.text.PlainDocument to implement the required method insertString(int offset, String string, AttributeSet attributes). This method internally invokes StringConstraint.checkInput(String proposedValue) when appropriate.


Rule Set Constraints (RSC) provide specific DRDs for drug amount, diluent amount, and hard and soft limits. RSC are used to change these settings dynamically to validate inputs based on drug unit and dosing unit. RSC aggregates several constraint objects to verify that entries are within valid ranges. In one example, drugAmount, diluentAmount, and limits have their own DRD and Constraint object, but each is unique to meet the targets needs. RSC is initialized with default values when constructed. Successive calls to setDrugAmountConstraints(drugLabelPK) adjust the drugAmount DRD. Similarly, calls to setDiluentAmountConstraint( ) adjust the diluentAmount DRD. In one example of the present invention, the only constraint is diluentAmount. Likewise, successive calls to setLimitConstraints(dosingUnitPK) adjust the limit amounts.


Rule Set Data Item (RSDI) is a specialized DataItem and acts as a data model. Getter/Setters are provided to get and set attributes in the various forms needed by RVDC (described below), RSE and RSV (described below). DataItems know how to add themselves in a SQL Server database. In one example of the present invention, RSV is implemented as a static object and not a private implementation of RSDI. This separation of responsibility makes the implementation and maintenance of RSV simpler.


Rule Set Data Model (RSDM) is a specialized AbstractDataModel that provides a virtual data store for all RSDI items that are being imported.


Rate Versus Dose Calculations (RVDC) calculate the delivery rate corresponding to a given dose, in the context of such variables as patient weight, drug concentrations, etc. In one example, RVDC is not tied to a particular infusion pump implementation. Also, in one example, the RVDC algorithm is purely algebraic. RSDI owns the data that is extracted by RSV and passed to RVDC to calculate either calculateDoseFromRate or calculateRateFromDose.


The Rule Set Validator (RSV) orchestrates the validation process for all rule set data fields. The RSV starts by resetting the constraints needed by drugAmount, diluentAmount and the limits. It systematically validates each field for conformance, as follows:

    • Length cannot be zero or blank and cannot exceed the maximum length.
    • Pixel length cannot exceed displayable area on pump.
    • Name is checked for invalid characters.


RSV is used to validate rule sets from different sources, including: user input, imported libraries, copied drugs from one location to another, and makes adjustments to CCA maximum rate settings. RSV is consistently and constantly used throughout the system to validate that a rule set is well formed, valid and will not violate the delivery conformance for the entire library. If a user attempts to enter data that violate a rule, the “save” button in the dialog box will be dimmed and disabled, forcing the user to change the data that violates the rule. FIG. 15 is a diagram showing an example of a dialog box used when editing a rule set for a drug. In this example, the user edits whatever is desired, and then clicks the “save” button. If the entries are not valid, the “save” button will be dimmed and the user will not be allowed to save the changes.



FIG. 16 shows one example of a rule set validator decision tree. The decision tree shown in FIG. 16 describes the basic logic used to assess the validity of rule set limits. Generally, the decision tree asks if the rule set is equal to “NONE”, “FULL”, or “LIMITED”, and then asks the other questions outlined in the decision tree to determine if the rule set is valid. FIG. 16 illustrates the dynamic checking that is done each time a user makes a keyboard or mouse entry while making or editing a rule set. FIG. 16 also shows how the RSV checks to see if such a delivery rate/dose would be acceptable based upon the dose limits. Other settings may also factored in or analyzed in a similar manner, such as the maximum rate CCA infuser setting.


Another feature of the present invention relates to Data Models. Data Models are used to import data into a drug library, copy from a source to a destination CCA library, and to edit CCA settings within a CCA Library. The following figures illustrate the relationship and high-level interactions between DrugLibraryManager (DLM) and RSDI. FIG. 22 shows the relationship between a DataModel and DataItem. For clarity, CCASettings and CCALibrary DataModel and DataItem are not shown in FIG. 22. FIG. 23 is a diagram illustrating the high-level interaction between the import process and RuleSetDataItem. As mentioned above, there are some similarities between an import and the RSE. For example, RSDI is validated by RSV. The import process consumes either a tab separated value (TSV) or a comma separated value (CSV) file, creating an RSDM object. RSDM is used to create a Drug Library, CCA, CCA Library View, and Master Drug Formulary (MDF) entries. FIGS. 24 and 24A show two preferred UML diagrams illustrating the high-level interaction between DrugLibraryManager (DLM) and RSDI when rule sets are copied from a target to a source CCA Library. Similarly, FIG. 25 illustrates the high-level interaction between DrugLibraryManager (DLM) and RSDI when CCA Settings are edited in the target CCA Library.


The present invention also has a specialized combo box editor called the Dose Rate Editor (DRE). The DRE is used to establish the DRD for drugAmount, diluentAmount and the limits. The DRE is unique because it makes special allowances for both dose rate input and the reserved word ‘None’. The DRE converts all absolute values of zero (e.g., “0”, “0.0”, “0.00”, “none”, etc.) to ‘None’ and strips off any trailing zero or decimal points for non-zero values.


As mentioned before, the present invention is capable of using both hard and soft limits simultaneously. In addition, various related reports can be generated from one or more infusion pumps. One type of report is a soft limit override report (discussed below). Following is an example of how soft limit override reports can be generated. Persistent storage design for SoftLimit Alert/Override report is driven by both specific requirements for the “saving” of the uploaded logs and by the indirect requirements for parsing the raw log data to identify clinical action, partial events, and duplicate log entries. In one example, all log data maintains an association with the Infusion pump from which it was uploaded.


Raw log data is persisted both for archiving purposes and to support direct reporting (listing) of the log contents. Prior to its persistence, the raw log data undergoes a first pass of parsing to remove those portions of the log that represent old data that has already been uploaded to the PC but remained stored in the infusion pump (because the log is not cleared following an upload). The following database tables are defined to hold the parsed log data.













Table Name
Purpose







UploadHistory
A record in this table represents a specific session involving the



upload of event log data from an Infuser.


UploadEvent
A record in this table represents a single, raw event as captured by,



and uploaded from, the Infuser.


EventType
A look up table of log event type of interest to the PC application


ClinicalAction
A record in this table represents a single attempt to execute a



program to administer a drug. Note that a clinical event is only



recorded in the database if it results in the occurrence of a



reportable event.










The first three tables listed, UploadHistory, UploadEvent, and EventType, support the existing functionality to persist the raw uploaded event data. The fourth table listed, ClinicalAction, is intended to provide the necessary context for an individual event (the Soft Limit Alert/Override) to generate a meaningful and useful report.


The individual fields of each of the tables described above are illustrated as follows. First, the fields from the UploadHistory are listed, along with a description of their purpose.













Field Name
Purpose







UploadHistoryID
A unique (sequential) identifier for an upload session. This is the



Primary Key for the table.


SerialNumber
A unique identifier for the Infuser from which the upload was



taken. This is a Foreign Key to the Pump table (existing).


CompositeVersion
This field holds the information necessary to uniquely identify the



Library installed on the Infuser


DateUploaded
The Date (and time) when the upload was successfully



completed.


State
Identifies the current state of the upload process. Possible



states include Uploaded, Consumed (completely parsed and



persisted)









Next, the fields from the UploadEvent are listed, along with a description of their purpose.













Field Name
Purpose







UploadEventID
A unique (sequential) identifier for an uploaded event. This is the



Primary Key for the table.


UploadHistoryID
The identifier of the UploadHistory from which this event was



created. Foreign Key to the UploadHistory table.


EventTypeID
The type of the event. Foreign key to the EventType table.


EventDate
The date stamp for a single log as uploaded from an infuser


EventData
The contents forsingle line of raw data as uploaded from an



Infuser.


DateCreated
The time that the event is added to the database.









Next, the fields from the EventType are listed, along with a description of their purpose.













Field Name
Purpose







EventTypeID
A unique (sequential) identifier for an event type. This is the



Primary Key for the table.


EventName
The name of the event. Note this table holds event types that are



of interest to the PC application for the purposes of parsing



reportable events. This will be a subset of the event types



produced by the Infuser.


DateCreated
The date that the item is added to the database.









Finally, the fields from the ClinicalAction are listed, along with a description of their purpose.













Field Name
Purpose







ClinicalAction ID
A unique (sequential) identifier for a clinical



action. This is the Primary Key for the table.


UploadHistoryID
The identifier of the Upload History from which



this clinical event was parsed. This is a



Foreign Key to the UploadHistory table.


UploadEventID
A unique (sequential) identifier for an



uploaded event.


CcaName
The name of the clinical care area



programmed for this action.


Status
Indicating whether all the data for this action



was available in the log (Complete). Partial if



only partial data was available.


Attempted Dose
The dose value that user input.


ProgrammedDose
The dose that is being delivered.


SoftLimit
The dose limit value


DosingUnits
The current dose units


SoftLimitType
Indicates the softlimt is upper or lower limit


OverrideType
Indicates the softlimitOverride type is alert or



override


InfuserChannel
The current infuser channel


StepNumber
The step that the softlimit is violate


DrugName
The drug name programmed for this action.


DrugConcentration
The drug concentration programmed for this



action.


DeliveryConfirmedProgramConfirmed
Indicates whether or not the delivery program



was confirmed.










In one example, all of the fields listed are required and are constrained to be “not null”. In this example, all data fields support a value of “not available” to indicate that a specific field has no value because it could not be retrieved from the event log (e.g. due to overwriting when the log exceeds 321 lines). The following diagram illustrates the data model to support the Soft Limit Alert or Override clinical event. FIG. 26 is a diagram illustrates a data model to support a soft limit alert or override clinical event.



FIG. 7 shows an example of one soft limit override report. FIG. 7A contains an explanation of the headings and data shown in FIG. 7. FIGS. 7B-E and 8A-D show examples of soft and hard limit override reports for several different drugs, in this example, dopamine, heparin, insulin, and Vancomycin. The reports shown in FIGS. 7B-7E list the type of alert presented (lower hard limit, lower soft limit, upper soft limit, upper hard limit) and the number of times each alert was presented. For each type of alert presented, the report also shows statistics relating to how the user responded to the alerts. In this example, the report indicates the number of times the alert was overridden or not overridden. In addition, the report also indicates the number of times “No” was entered by a user when asked to confirm the entry of information. FIGS. 8A-8D show another example of alert and override reports. The reports shown in FIGS. 8A-8D are similar the reports shown in FIGS. 7B-7E, except each alert is separated by CCA (in this example, ICU and MedSurg). It is apparent from these examples that any desired information can be collected and reported by the present invention.


One advantage of the present invention is that both hard and soft limits can be provided for each drug, and any drug/CCA combination can be ascribed one, two, three, or four limits. When the capability of providing both hard and soft limits exists, there the sixteen combinations of limits that can be used. Each of the four limits can contain a value specifying a limit, or the “limit” can be unrestricted (indicated by None in the appropriate field). These two possibilities exist for each limit, i.e., the lower hard limit, lower soft limit, upper soft limit and upper hard limit). This feature allows a user to configure a device in various combinations, such as a hard upper limit only, hard and soft upper and lower limits, hard and soft upper limits (no lower limits), hard and soft lower limits (no upper limits), etc. In the example of two sets of upper and lower limits, there are 16 possible combinations of configurations. If additional sets of limits are used, more combinations are possible. In one embodiment, hard limits are the upper and/or lower dose limits for the selected drug and selected CCA that cannot be overridden by a user. The hard limit in another embodiment may require or allow supervisory override. The hard limits, authority levels, and overridability, are defined by a hospital for each drug in its drug library. The hard limits for a particular drug may vary across different CCAs, if assigned.


In one embodiment, soft limits are upper and/or lower dose limits for the selected drug and selected CCA that can be overridden by a user. Soft limits for a particular drug, if assigned, may vary across CCAs. A set of rules is provided for the drug library that triggers alerts or warnings when soft limits are reached. The warnings require an explicit override step on the part of the operator. Similarly a set of rules is provided for the drug library that provide hard limits on the range of delivery rates the user is allowed to program. For example, if a lower soft limit is set to 10 mL/hr and the clinician enters 9 mL/hr, the infuser will display a soft limit override alert. This alert, which is recorded in the infuser's history log, notifies the clinician that the entry is outside the range of the soft limits set for that drug entry. The clinician can choose to continue programming using the override, or cancel the override and re-enter another value. If the clinician chooses to override the soft limit, the event is recorded separately in the infuser's history log. Hard and soft limits can be set on various other drug parameters. Examples include a dosage rates, drug delivery time, drug concentration, the weight of a patient, the volume to be infused (VTBI), etc.


Another use of hard and/or soft limits relates to correct data entry. For example, a hard limit can be set on time period entries so that a user can only enter values between 0 and 59. In this example, the system will realize a data entry error and force the user to enter a value in the valid range. In another example, for various drug fields, only certain values or ranges will be allowed to be entered. 15A shows examples of values that may be entered for drug unit, drug amount, diluent amount, delivery dose/rate units, and hard and soft limit fields. If a user attempts to enter other values, the system will force the user to enter a valid field, or will generate an alert or alarm.


The invention also allows the import and export of drug libraries from one computer to another. Before a library can be imported, it must be exported. Generally, a drug library can be exported to a finalized drug Library (FDL) having a predefined format, which makes the library safely and securely portable to other computers where they can be imported and set as an active library. For example, for a first PC having an active library, the library can be exported into a binary format, and moved (via a network, computer readable media, etc.) to a second PC, where it is imported, therefore synchronizing the libraries at the first and second PCs. The special file extension (FDL) and recognition by the software between computers is required.


When an FDL is exported, the entire drug library is first “selected” from the database, using the SelectEntireDrugLibrary stored procedure (see below). That procedure actually contains several select statements, with one statement per table. The tables are the same as for copy. For each table, the export method serializes the table name, number of rows and columns, then each row is serialized, column by column. Note that the original database index values are serialized. When the library is read from the file, the index values will no longer be valid—but should be mapped, the same as if the library were being copied. In one example, the FDL Files are “read only” files. Since the FDL files are in Java-serialized format, a FDL file is not easily modified by a user with ordinary software applications. This feature is part of the reason for using serialization—to discourage users from tampering with finalized drug libraries.


When an FDL is imported, first all the serialized information is read into memory, in the form of a three-dimensional array. There are three array dimensions, one dimension for the tables, one dimension for the rows, and one dimension for the columns. The sizes of the row and column dimensions may be different for each table. This “raw” data is inserted into the database, table-by-table, row-by-row. Also, index mappings may be performed along the way. Next, as the rows are inserted, new index values will be generated, and are stored in a map, similar to what happens during the copy operation. Some tables may contain indexes to other, previously inserted tables. These indexes are converted from the original values to the new values, using the generated map. These converted index values are the ones that are inserted into the new rows. After an FDL has been stored in the database, it becomes the Finalized Drug Library, making another Finalized Drug Library into an Archived library.


Following is a description of FDLData.java, which lets the FDL import know which order the tables are stored in the array, what the index dependencies are, which columns to store in the map, which column values need to be mapped to new values before they can be inserted, etc.


It is important to realize that, just as with copying a drug library, the order in which tables are processed during an FDL import is important. That order is encoded in the FDLData.java file as enumerated constants. Following is an example of such enumerated constants:


















public static final int DRUG_LIBRARY_TABLE
=1;



public static final int DOSING_UNITS_TABLE
=2;



public static final int DRUG_AMOUNTS_TABLE
=3;



public static final int DILUENT_UNITS_TABLE
=4;



public static final int DRUG_LABELS_TABLE
=5;



public static final int DRUG_CLASS_TABLE
=6;



public static final int DRUGS_TABLE
=7;



public static final int CONCENTRATION_TABLE
=8;



public static final int RULE_SET_TABLE
=9;



public static final int CCA_TABLE
=10;



public static final int DEVICE_SETTINGS_TABLE
=11;



public static final int CCA_SETTINGS_TABLE
=12;



public static final int INFUSER_SETTINGS_TABLE
=13;



public static final int DRUG_FORMULARY_TABLE
=14;



public static final int CCA_LIBRARY_TABLE
=15;



public static final int TABLE_COUNT
=16;










These constants can be used as indexes into the three-dimensional array of raw data described above. This section of code may also be generated by the PostSchemaChange.sql file, in case changes have been made to the database schema.


For each table that gets exported/imported there is an instance of TableInfo, which keeps track of the table name, the number of columns, which of its columns, if any, other tables might depend on (the idColumn), and finally, a set of indexes to tables that this table depends on. The “idColumn”, if specified, is generated by the database for each row of that table, as the rows are inserted. The old value (from the serialized file) and the new value (from the database row insertion) are stored in an index map. Then, every other in-memory table that references the old index is updated to contain the new index before its rows are inserted. For example, the “idColumn” of the RuleSet table shown below is its RuleSetID column, which happens to be the 2nd column in the TableInfo table. Thus, the “idColumn” in the TableInfo instance for RuleSet equals 1 (the first column is 0, the 2nd column is 1, . . . ). Now, assume that when the FDL was exported, there was a row in the RuleSet table where the RuleSetID was equal to 5047:


RuleSet (Slightly Simplified):



















RuleSetID
DrugLibraryID
DrugLabelID
DosingUnitID
LHL
LSL
USL
UHL







. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .


5047
1038
2
0
None
10
200
None


. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .










The CcaLibrary and DrugFormulary tables (shown below) each have a RuleSet dependency—their RuleSetID columns.


CcaLibrary (Slightly Simplified):

















CcaLibraryID
DrugLibraryID
RuleSetID
CcaID
DrugFormularyID
DisplayOrder







. . .
. . .
. . .
. . .
. . .
. . .


3252
1038
5047
2108
4217
0


. . .
. . .
. . .
. . .
. . .
. . .










Drug Formulary:















DrugFormularyID
DrugLibraryID
ConcentrationID
RuleSetID







. . .
. . .
. . .
. . .


4217
1038
6150
5047


. . .
. . .
. . .
. . .










Now assume that when the FDL is imported, that particular row of the RuleSet table (shown below) is given a new index value of 5122.


RuleSet (Slightly Simplified):



















RuleSetID
DrugLibraryID
DrugLabelID
DosingUnitID
LHL
LSL
USL
UHL







. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .


5047
1038
2
0
None
10
200
None


. . .
. . .
. . .
. . .
. . .
. . .
. . .
. . .


5122
1039
2
0
None
10
200
None










Later, before the CcaLibrary or DrugFormulary tables are inserted, any RuleSetID values of 5047 are first changed to 5122. The “idColumn” setting of 1 tells the FDL import code to store the 5047 to 5122 mapping.


Mapping (In Memory, Not a Database Table):
















OldIndexValue
NewIndexValue









. . .
. . .



5047
5122



. . .
. . .











The 5047 values in the CcaLibrary and DrugFormulary tables are changed to 5122 while they are still in memory—in the three dimensional table of raw data. After those tables have been processed, the CcaLibrary and DrugFormularyID tables are shown below.


CcaLibrary (Slightly Simplified):

















CcaLibraryID
DrugLibraryID
RuleSetID
CcaID
DrugFormularyID
DisplayOrder







. . .
. . .
. . .
. . .
. . .
. . .


3252
1038
5047
2108
4217
0


. . .
. . .
. . .
. . .
. . .
. . .


3333
1039
5122
2222
4444
0


. . .
. . .
. . .
. . .
. . .
. . .










Drug Formulary:















DrugFormularyID
DrugLibraryID
ConcentrationID
RuleSetID







. . .
. . .
. . .
. . .


4217
1038
6150
5047


. . .
. . .
. . .
. . .


4444
1039
6666
5122


. . .
. . .
. . .
. . .









Referring back to the FDLData.java file, various sections of the file are automatically generated by the PostSchemaChange.sql file. They can be cut and pasted from the output of that file into the java code. Specifically, the table order constants (as shown above), and the TableInfo array and its contents can be generated in the event of a database schema change.


The PostSchemaChange.sql file also generates most of the SelectEntireDrugLibrary stored procedure (described below) at the same time. Again, the SQL code it generates can be cut and pasted into the proper place in the SelectEntireDrugLibrary.sql file.


When a FDL is to be exported, the data that makes up the library is obtained from the database (so it can be serialized to a file). The SelectEntireDrugLibrary stored procedure does that. The procedure utilizes several select statements, selecting the tables in a specific order, and selecting the columns of any given table in a specific order.


Since the order of the tables, and the order of the columns within those tables is important to the FDL import code that reconstructs a drug library, it is essential that the FDL export, FDL import, and SelectEntireDrugLibrary code be kept in sync with each other. The slightest change in the database schema can necessitate changes in FDLData.java and SelectEntireDrugLibrary, as well as the CopyDrugLibrary stored procedure. The slightest error (mismatch) will stop things from working properly.


Except for the CopyDrugLibrary code, most of the java and SQL changes can be produced by running the PostSchemaChange.sql file after the new schema is in place. Simply cut and paste the generated code over the matching/similar code in those files. The CopyDrugLibrary code changes can also be automated.


One feature of the present invention is that data can be imported to and exported from the system. Library text files that use either Comma Separated Values (CSV) or Tab Separated Values (TSV) can be imported by the system. One unique feature is the entire file must pass the RSV checks specified above or the entire import is considered invalid.


It will be appreciated by one skilled in the art that the present invention is applicable to a variety of pumps or medical devices and not limited to the pumps with which it is described herein. Furthermore, one skilled in the art will appreciate that the connections between the pumps and the computer could be wireless or hard-wired, without detracting from the invention. Wireless communication engines can be connected to the pump and the computer and use a wireless network utilizing communication protocols such as BLUETOOTH™ (IEEE 802.15) or other protocols such as those described in IEEE 802.11, 802.11a, 802.11b, and 802.11g. Communication within the wireless network may utilize radio frequency electromagnetic radiation, infrared radiation, or other means for accomplishing wireless communication between network elements.


In one example, the plug and play module 4 can house or encase a wireless communication or connectivity engine. Conventional wireless communication modules for medical pumps have been of the external plug-in, bolt-on type for optimal reception and transmission. These conventional communications modules add significantly to the space required for the pump and alter its profile. They can be damaged or dislodged if the pump is dropped. Furthermore, there are stringent standards for maximum electrical emissions from medical equipment to prevent potential interference with other medical equipment. The wireless plug and play module 4 of the present invention does not substantially increase the space occupied by the pump. With the improved antenna design described below, placing the plug and play module 4 inside the pump housing 2 still provides good position/orientation tolerant reception and transmission characteristics and provides the surprising result of lower, better controlled electronic emissions from the device.


As mentioned above, an infusion pump of the present invention is capable of being connected to various other devices. In one example, the present invention uses a connectivity engine to provide system functions, in addition to enabling a pump to connect to a variety of other devices. Following is one example of a connectivity engine which can be used with the present invention. In the example described, the various features and capabilities can be customized as desired.


The connectivity engine is an assembly inside the housing of an infuser with the purpose of providing key system functions and enabling the infuser to connect to a variety of external systems including medication management units (MMU), hospital information systems (HIS), pharmacy information system (PhIS), and other medical information systems through both wired and wireless communication links. The connectivity engine can interface via data and address buses on its printed wiring assembly to the CPU printed wiring assembly via a board to board connector. In one example, the connectivity engine supports about 1-2 Mbytes of read-only program and 1 M-byte or more of read/write data memories for the infuser CPU printed wiring assembly. The connectivity engine can communicate with a host computer via a serial data port, which is externally located on the rear of the infuser unit. In one example, the data port is electrically isolated.


In this example, the connectivity engine includes a front panel lockout switch, which is externally accessible on the rear of the unit. The connectivity engine may also include a nurse call interface, which is externally located on the rear of the unit. The nurse call interface allows use with a nurse call device, such as a switch held by a patient that allows the patient to send an alarm message to a nurse. The connectivity engine may also include an alarm volume control, which is accessible from the rear of the instrument. This control will adjust the volume level for an audible alarm to alert the user to errors, warnings, etc.


The connectivity engine is a modular and intelligent printed wiring assembly capable of supporting the interconnection of an infuser with a variety of external systems for the purpose of establishing bi-directional communications between the infuser and external systems. Examples of external systems may include medication management units (MMU), medical information systems, HIS, and external wireless Access Points. Other examples of external systems include one or more PCs for downloading drug libraries and software to the infuser and uploading logs from the infuser.


As mentioned above, the present invention is capable of both wired and wireless communications. Examples of wired interfaces that may be supported include Ethernet 10BaseT and 100BaseT standard, as well as Megabit and fiber optic interfaces. Examples of wireless interfaces that may be supported include IEEE802.11a/b/g, as well as any other desired interfaces. The connectivity engine can support various network protocols, including XML, HTML, ftp, and Telnet services.


In one example, the present invention normally operates using either a wired or wireless interface. In another example, the invention can simultaneously use both wired and wireless interfaces. In this example, when a fault is detected in either mode, all communications automatically can switch to the working mode.


The connectivity engine hardware can take on many forms, depending on the functionality and capabilities desired. In one example, the connectivity engine includes the following sub-circuits: CPU memory—RAM and flash, external serial interface, nurse call interface, audio volume control, lockout switch, connectivity engine controller, Ethernet interface, wireless interface, and antenna assembly. The following external connectors can also be included: Ethernet RJ-45 connector, RF connector for connecting the Wi-Fi transceiver to the Antenna printed wiring assembly, RS232 serial port DB9 connector, and Nurse Call Interface connector.



FIGS. 9-11 are block diagrams of an exemplary connectivity engine that may be used with the present invention and fully enclosed within the pump housing rather than in a removable plug and play module. FIG. 9 shows a user interface controller (UIC) 20, which is connected to a connectivity engine 22 via a universal serial bus (USB). Of course, other interfaces could also be used (e.g., RS232 serial interface, parallel interface, etc.). The connectivity engine 22 is an input/output board shown in FIG. 9 with Ethernet and WiFi connections. FIG. 10 is a block diagram of a connectivity engine including a processor 24. The processor 24 is connected to an Ethernet transceiver 26 and transformer 28 to provide an Ethernet interface to communicate with one or more PCs 10. This interface could also be provided wirelessly. The processor is also connected to a USB controller 30. The USB controller 30 is connected over a USB interface to UIC USB client 32 and to RF transceiver 34.


The RF transceiver 34 is shown with two antennas 36 and 38. While the present invention may include just one antenna, two antennas can improve the performance of the invention. Since the communication between the invention and other devices can be critical, it is desirable to provide the most reliable wireless connection possible. Two diverse antennas optimize the wireless communication coverage of the invention. The invention uses a combination of two different diversity schemes, spatial diversity and pattern diversity. Traditionally, in spatial diversity two identical antennas are located at two separate locations to provide diversity reception to a common receiver. In this case, the scheme not only separates the antennas physically but also achieves pattern diversity by placing the two antennas orthogonally. This way, peaks in one antenna fill out the nulls of the other antenna such that that combined radiation pattern looks more omnidirectional than just a single antenna. The antenna diversity scheme achieves several objectives. First, it is desirable to have the antenna(s) not so apparent externally, making it desirable to use an internally embedded antenna(s). Second, in most applications, the invention must meet the EMC requirements specified in the IEC 60601-1-2, 2nd Edition standard, which limits the amount of emissions a device can emit. The use of two diverse antennas helps to achieve these objectives. In one example, the antenna(s) used with the present invention are enclosed within the housing of the infusion pump. This help to keep dirt, harmful solvents and debris away from the antennas, enhances control of emissions, as well as reduces the chance of damage to an antenna.


In another example, the connectivity engine includes memory used as cache for temporarily storing information. The cache can make the system work more efficiently and more reliably.



FIG. 11 is a block diagram of the wireless interface shown in FIG. 10 and shows a baseband processor and medium access controller 40, which includes a USB interface for communication with a host computer. The processor 40 is connected to a modulator/demodulator 42, an RF/IF converter 44, and a power amplifier 46. The antennas 36 and 38 are driven by the power amplifier 46 and the RF/IF converter 44.



FIGS. 12A-15 are electronics system diagrams of one example of the present invention, as applied to the Abbott PLUM A+® Infuser. FIGS. 12A-12D shows a CPU and a communication or connectivity engine. The communication engine facilitates communication with other devices via wired or wireless interfaces. The communication engine can utilize the same orthogonally arranged antennas as described above relative to FIGS. 9-11. FIG. 12 also shows a digital I/O chip for interfacing with various components, such as switches and user controls, a nurse call jack, keypads, alarm speakers, LEDs, etc. FIG. 13 shows the power supply subsystem, including power supply circuitry and an isolation bather. FIG. 14 shows the mechanism subsystem, including pressure sensors, air sensors, motor position sensors, and a motor drive.



FIG. 17 is an electronic system block diagram of a patient-controlled analgesia (PCA) pump. FIGS. 18 and 19 are electronic system interface block diagrams of a connectivity engine that may be used with the PCA pump shown in FIG. 17. FIG. 17 includes a power supply, which supplies power to the system. A microcontroller interfaces with various components of the system, including a keypad, a patient pendent, serial port, bar code reader, various sensors, various switches, motor drivers, displays and LED indicators, and a speaker.



FIG. 18 is a block diagram of a connectivity engine that may be used with the PCA system shown in FIG. 17. FIG. 18 shows a connectivity engine and several interfaces including Ethernet, WiFi, an external RS232 serial interface, and an RS232 serial interface to the host device. FIG. 18 also illustrates that the connectivity engine can draw power (via a power connector) from the PCA pump (FIG. 17). The PCA pump generates a motor voltage VMOT for powering the various motors. The same voltage VMOT can be used to power the connectivity engine.



FIG. 19 is a more detailed block diagram of the connectivity engine of FIG. 18. The connectivity engine includes a connectivity engine controller (CEC), which is a wired/wireless connectivity module incorporating both a Ethernet processor and an 802.11b wireless transceiver. An Ethernet transceiver and all necessary circuitry to provides a 10/100 Base T interface through an RJ-45 jack. A USB controller and all the necessary circuitry controls a USB (host) interface with the WiFi. The two RS232 ports are connected to a system bus. The connectivity engine also includes FLASH and SDRAM memory.


In the preceding detailed description, the invention is described with reference to specific exemplary embodiments thereof. Various modifications and changes may be made thereto without departing from the broader scope of the invention as set forth in the claims. The specification and drawings are, accordingly, to be regarded in an illustrative rather than a restrictive sense.

Claims
  • 1. A system for controlling operating of an infusion pump, the system comprising: a display configured to display an input field corresponding to a first parameter, wherein the input field is configured to receive a first input from a user for the first parameter, wherein the first parameter relates to an infusion property of the first drug; anda one or more hardware processors in electronic communication with the display, the one or more hardware processors configured to: access a generalized version of a drug library;retrieve a rule set corresponding to the first parameter and the first drug from the generalized version of the drug library;retrieve operating parameters corresponding to the first parameter and the first drug from the generalized version of the drug library;validate the first input based on the rule set and the operating parameters;dynamically control the input field based on the validation of the first input;generate a first customized drug library based on the validated first input for a host computer that is in connection with a plurality of infusion pumps, wherein the first customized drug library is in an Extensible Markup Language (XML) data format;generate a second customized drug library to operate the infusion pump based on the validated first input, wherein the second customized drug library is in a pump specific format, wherein the first customized drug library and the second customized drug library correspond to same underlying content that correspond to content in the generalized version of the drug library; andvalidate the second customized drug library in the pump specific format with the first customized drug library in the XML data format.
  • 2. The system of claim 1, wherein the first parameter comprises at least one or more of a dosage rate, drug delivery time, drug concentration, or a volume to be infused (VTBI).
  • 3. The system of claim 1, wherein the operating parameters comprise at least one or more of an upper hard limit, an upper soft limit, a lower hard limit, or a lower soft limit.
  • 4. The system of claim 1, wherein the one or more hardware processors is further configured to retrieve the generalized drug library from a server.
  • 5. The system of claim 1, wherein the rule set comprises a manufacturer defined rule set.
  • 6. The system of claim 1, wherein the rule set comprises a user defined rule set.
  • 7. The system of claim 1, wherein the validation is further based on a location of the infusion pump.
  • 8. The system of claim 1, wherein the one or more hardware processors is further configured to validate the first input for each keystroke.
  • 9. The system of claim 1, wherein the one or more hardware processors is further configured to generate an alert based on the validation.
  • 10. A method for controlling operating of an infusion pump, the method comprising: displaying an input field corresponding to a first parameter, wherein the input field is configured to receive a first input from a user for the first parameter, wherein the first parameter relates to an infusion property of the first drug;accessing a generalized version of a drug library;retrieving a rule set corresponding to the first parameter and the first drug from the generalized version of the drug library;retrieving operating parameters corresponding to the first parameter and the first drug from the generalized version of the drug library;validating the first input based on the rule set and the operating parameters;dynamically controlling the input field based on the validation of the first input;generate a first customized drug library based on the validated first input for a host computer that is in connection with a plurality of infusion pumps, wherein the first customized drug library is in an Extensible Markup Language (XML) format;generating a second customized drug library for operating the infusion pump based on the validated first input, wherein the second customized drug library is in a pump specific format, wherein the first customized drug library and the second customized drug library correspond to same underlying content that correspond to content in the generalized version of the drug library; andvalidating the second customized drug library in the pump specific format with the first customized drug library in the XML data format.
  • 11. The method of claim 10, wherein the first parameter comprises at least one of a dosage rate, drug delivery time, drug concentration, or a volume to be infused (VTBI).
  • 12. The method of claim 10, wherein the operating parameters comprise at least one of an upper hard limit, an upper soft limit, a lower hard limit, and a lower soft limit.
  • 13. The method of claim 10, further comprising retrieving the generalized drug library from a server.
  • 14. The method of claim 10, wherein the rule set comprises a manufacturer defined rule set.
  • 15. The method of claim 10, wherein the rule set comprises a user defined rule set.
  • 16. The method of claim 10, wherein the validation is further based on a location of the infusion pump.
  • 17. The method of claim 10, further comprising validating the first input for each keystroke.
  • 18. The method of claim 10, further comprising generating an alert based on the validation.
CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority based upon U.S. Nonprovisional application Ser. No. 10/783,877 filed Feb. 20, 2004 and U.S. Provisional Application Ser. No. 60/519,646 filed Nov. 13, 2003 and U.S. Provisional Application Ser. No. 60/527,550 filed Dec. 5, 2003, which are expressly incorporated herein in their entirety.

US Referenced Citations (1078)
Number Name Date Kind
4024864 Davies et al. May 1977 A
4055175 Clemens et al. Oct 1977 A
4151845 Clemens May 1979 A
4213454 Shim Jul 1980 A
4240438 Updike et al. Dec 1980 A
4280494 Cosgrove et al. Jul 1981 A
4308866 Jeliffe Jan 1982 A
4370983 Lichtenstein et al. Feb 1983 A
4373527 Fischell Feb 1983 A
4392849 Petre et al. Jul 1983 A
4395259 Prestele et al. Jul 1983 A
4457751 Rodler Jul 1984 A
4464170 Clemens Aug 1984 A
4469481 Kobayashi Sep 1984 A
4475901 Kraegen et al. Oct 1984 A
4494950 Fischell Jan 1985 A
4498843 Schneider et al. Feb 1985 A
4515584 Abe et al. May 1985 A
4526568 Clemens et al. Jul 1985 A
4529401 Leslie et al. Jul 1985 A
4543955 Schroeppel Oct 1985 A
4551133 Zegers de Beyl et al. Nov 1985 A
4553958 LeCocq Nov 1985 A
4559037 Franetzki et al. Dec 1985 A
4613937 Batty Sep 1986 A
4624661 Arimond Nov 1986 A
4633878 Bombardieri Jan 1987 A
4634426 kamen Jan 1987 A
4634427 Hannula et al. Jan 1987 A
4674652 Aten et al. Jun 1987 A
4676776 Howson et al. Jun 1987 A
4679562 Luksha Jul 1987 A
4685903 Cable et al. Aug 1987 A
4695954 Rose Sep 1987 A
4696671 Epstein et al. Sep 1987 A
4714462 DiDomenico Dec 1987 A
4722734 Kolin Feb 1988 A
4731051 Fischell Mar 1988 A
4741732 Crankshaw et al. May 1988 A
4756706 Kerns et al. Jul 1988 A
4776842 Franetzki et al. Oct 1988 A
4785969 McLaughlin Nov 1988 A
4803625 Fu et al. Feb 1989 A
4835372 Gombrich et al. May 1989 A
4838275 Lee Jun 1989 A
4838856 Mulreany et al. Jun 1989 A
4838857 Strowe et al. Jun 1989 A
4854324 Hirschman et al. Aug 1989 A
4857716 Gombrich et al. Aug 1989 A
4858154 Anderson et al. Aug 1989 A
4898578 Rubalcaba, Jr. Feb 1990 A
4908017 Howson et al. Mar 1990 A
4933873 Kaufman et al. Jun 1990 A
4943279 Samiotes et al. Jul 1990 A
4946439 Eggers Aug 1990 A
4953745 Rowlett Sep 1990 A
4978335 Arthur, III Dec 1990 A
5000739 Kulisz et al. Mar 1991 A
5010473 Jacobs Apr 1991 A
5014698 Cohen May 1991 A
5016172 Dessertine May 1991 A
5026084 Paisfield Jun 1991 A
5034004 Crankshaw Jul 1991 A
5041086 Koenig et al. Aug 1991 A
5058161 Weiss Oct 1991 A
5078683 Sancoff et al. Jan 1992 A
5084828 Kaufman et al. Jan 1992 A
5088981 Howson et al. Feb 1992 A
5097505 Weiss Mar 1992 A
5100380 Epstein et al. Mar 1992 A
5102392 Sakai et al. Apr 1992 A
5104374 Bishko et al. Apr 1992 A
5109850 Blanco et al. May 1992 A
5131816 Brown Jul 1992 A
5142484 Kaufman et al. Aug 1992 A
5153827 Coutre et al. Oct 1992 A
5157640 Backner Oct 1992 A
5161222 Montejo et al. Nov 1992 A
5177993 Beckman et al. Jan 1993 A
5181910 Scanlon Jan 1993 A
5190522 Wocicki et al. Mar 1993 A
5199439 Zimmerman et al. Apr 1993 A
5200891 Kehr et al. Apr 1993 A
5216597 Beckers Jun 1993 A
5221268 Barton et al. Jun 1993 A
5230061 Welch Jul 1993 A
5243982 Möstl et al. Sep 1993 A
5244463 Cordner, Jr. et al. Sep 1993 A
5249260 Nigawara et al. Sep 1993 A
5256156 Kern et al. Oct 1993 A
5256157 Samiotes et al. Oct 1993 A
5261702 Mayfield Nov 1993 A
5317506 Coutre et al. May 1994 A
5319355 Russek Jun 1994 A
5319363 Welch et al. Jun 1994 A
5330634 Wong et al. Jul 1994 A
5338157 Blomquist Aug 1994 A
5341476 Lowell Aug 1994 A
5364346 Schrezenmeir Nov 1994 A
5366346 Danby Nov 1994 A
5368562 Blomquist et al. Nov 1994 A
5373454 Kanda et al. Dec 1994 A
5376070 Purvis et al. Dec 1994 A
5378231 Johnson et al. Jan 1995 A
5389071 Kawahara et al. Feb 1995 A
5389078 Zalesky et al. Feb 1995 A
5417222 Dempsey et al. May 1995 A
5423748 Uhala Jun 1995 A
5429602 Hauser Jul 1995 A
5431627 Pastrone et al. Jul 1995 A
5432777 Le Boudec et al. Jul 1995 A
5445621 Poli et al. Aug 1995 A
5447164 Shaya et al. Sep 1995 A
5455851 Chaco et al. Oct 1995 A
5461365 Schlager et al. Oct 1995 A
5464392 Epstein et al. Nov 1995 A
5465082 Chaco Nov 1995 A
5485408 Blomquist Jan 1996 A
5486286 Peterson et al. Jan 1996 A
5493430 Lu et al. Feb 1996 A
5496273 Pastrone et al. Mar 1996 A
5505828 Wong et al. Apr 1996 A
5507288 Bocker et al. Apr 1996 A
5507786 Morgan et al. Apr 1996 A
5508499 Ferrario Apr 1996 A
5515713 Saugues et al. May 1996 A
5520637 Pager et al. May 1996 A
5522798 Johnson et al. Jun 1996 A
5547470 Johnson et al. Aug 1996 A
5554013 Owens et al. Sep 1996 A
5562615 Nassif Oct 1996 A
5577169 Prezioso Nov 1996 A
5582323 Kurtenbach Dec 1996 A
5582593 Hultman Dec 1996 A
5594786 Chaco et al. Jan 1997 A
5598519 Narayanan Jan 1997 A
5620608 Rosa et al. Apr 1997 A
5630710 Tune et al. May 1997 A
5636044 Yuan et al. Jun 1997 A
5643212 Coutre et al. Jul 1997 A
5651775 Walker et al. Jul 1997 A
5658131 Aoki et al. Aug 1997 A
5658250 Blomquist et al. Aug 1997 A
5665065 Colman et al. Sep 1997 A
5669877 Blomquist Sep 1997 A
5672154 Sillén et al. Sep 1997 A
5681285 Ford Oct 1997 A
5685844 Marttila Nov 1997 A
5687717 Halpern et al. Nov 1997 A
5689229 Chaco et al. Nov 1997 A
5697899 Hillman et al. Dec 1997 A
5699509 Gary et al. Dec 1997 A
5713856 Eggers et al. Feb 1998 A
5718562 Lawless et al. Feb 1998 A
5719761 Gatti et al. Feb 1998 A
5733259 Valcke et al. Mar 1998 A
5738102 Lemelson Apr 1998 A
5744027 Connell et al. Apr 1998 A
5752621 Passamante May 1998 A
5754111 Garcia May 1998 A
5764034 Bowman et al. Jun 1998 A
5764159 Neftel et al. Jun 1998 A
5772635 Dastur et al. Jun 1998 A
5774865 Glynn Jun 1998 A
5778256 Darbee Jul 1998 A
5778345 McCartney Jul 1998 A
5781442 Engleson et al. Jul 1998 A
5782805 Meinzer et al. Jul 1998 A
5788669 Peterson Aug 1998 A
5797515 Lift et al. Aug 1998 A
5800387 Duffy et al. Sep 1998 A
5814015 Gargano et al. Sep 1998 A
5822544 Chaco et al. Oct 1998 A
5822715 Worthington et al. Oct 1998 A
5827179 Lichter et al. Oct 1998 A
5832448 Brown Nov 1998 A
5836910 Duffy et al. Nov 1998 A
5850344 Conkright Dec 1998 A
5867821 Ballantyne et al. Feb 1999 A
5870733 Bass et al. Feb 1999 A
5871465 Vasko Feb 1999 A
5873731 Predergast Feb 1999 A
5885245 Lynch et al. Mar 1999 A
5897493 Brown Apr 1999 A
5897498 Canfield, II et al. Apr 1999 A
5910252 Truitt et al. Jun 1999 A
5912818 McGrady et al. Jun 1999 A
5915240 Karpf Jun 1999 A
5920054 Uber, III Jul 1999 A
5920263 Huttenhoff et al. Jul 1999 A
5924074 Evans Jul 1999 A
5931764 Freeman et al. Aug 1999 A
5935099 Peterson et al. Aug 1999 A
5935106 Olsen Aug 1999 A
5941846 Duffy et al. Aug 1999 A
5956501 Brown Sep 1999 A
5957885 Bollish et al. Sep 1999 A
5960085 de la Huerga Sep 1999 A
5961448 Swenson et al. Oct 1999 A
5967559 Abramowitz Oct 1999 A
5971594 Sahai et al. Oct 1999 A
5975081 Hood et al. Nov 1999 A
5990838 Burns et al. Nov 1999 A
5997476 Brown Dec 1999 A
6000828 Leet Dec 1999 A
6003006 Colella et al. Dec 1999 A
6012034 Hamparian et al. Jan 2000 A
6017318 Gauthier et al. Jan 2000 A
6021392 Lester et al. Feb 2000 A
6024539 Blomquist Feb 2000 A
6032155 de la Huerga Feb 2000 A
6032676 Moore Mar 2000 A
6073106 Rozen et al. Jun 2000 A
6104295 Gaisser et al. Aug 2000 A
6112182 Akers et al. Aug 2000 A
RE36871 Epstein et al. Sep 2000 E
6115390 Chuah Sep 2000 A
6122536 Sun et al. Sep 2000 A
6126637 Kriesel et al. Oct 2000 A
6135949 Russo et al. Oct 2000 A
6150942 O'Brien Nov 2000 A
6151643 Cheng et al. Nov 2000 A
6157914 Seto et al. Dec 2000 A
6159147 Lichter et al. Dec 2000 A
6167567 Chiles et al. Dec 2000 A
6182667 Hanks et al. Feb 2001 B1
6189105 Lopes Feb 2001 B1
6195589 Ketcham Feb 2001 B1
6208974 Campbell et al. Mar 2001 B1
6222323 Yamashita et al. Apr 2001 B1
6223440 Rashman May 2001 B1
6226277 Chuah May 2001 B1
6227371 Song May 2001 B1
6234176 Domae et al. May 2001 B1
6241704 Peterson et al. Jun 2001 B1
6248067 Causey, III et al. Jun 2001 B1
6249705 Snell Jun 2001 B1
6257265 Brunner et al. Jul 2001 B1
6259355 Chaco et al. Jul 2001 B1
6269340 Ford et al. Jul 2001 B1
6270455 Brown Aug 2001 B1
6271813 Palalau Aug 2001 B1
6277072 Bardy Aug 2001 B1
6280380 Bardy Aug 2001 B1
6283761 Joao Sep 2001 B1
6285665 Chuah Sep 2001 B1
6292860 Cochcroft, Jr. Sep 2001 B1
6312378 Bardy Nov 2001 B1
6327254 Chuah Dec 2001 B1
6330008 Razdow et al. Dec 2001 B1
6339718 Zatezalo et al. Jan 2002 B1
6346886 de la Huerga Feb 2002 B1
6363282 Nichols et al. Mar 2002 B1
6371719 Hildebrandt Apr 2002 B1
6377548 Chuah Apr 2002 B1
6388951 Matsumoto et al. May 2002 B1
6406426 Reuss et al. Jun 2002 B1
6408330 de la Huerga Jun 2002 B1
6418334 Unger et al. Jul 2002 B1
6427088 Bowman et al. Jul 2002 B1
6428483 Carlebach Aug 2002 B1
6442432 Lee Aug 2002 B2
6469991 Chuah Oct 2002 B1
6475180 Peterson et al. Nov 2002 B2
6482158 Mault Nov 2002 B2
6485418 Yasushi et al. Nov 2002 B2
6494694 Lawless et al. Dec 2002 B2
6494831 Koritzinsky Dec 2002 B1
6497680 Holst et al. Dec 2002 B1
6514460 Fendrock Feb 2003 B1
6517482 Eiden et al. Feb 2003 B1
6519569 White et al. Feb 2003 B1
6520930 Critchlow et al. Feb 2003 B2
6540672 Simonsen et al. Apr 2003 B1
6542902 Dulong et al. Apr 2003 B2
6544212 Galley et al. Apr 2003 B2
6544228 Heitmeier Apr 2003 B1
6546350 Hartmann et al. Apr 2003 B1
6551276 Mann et al. Apr 2003 B1
6554798 Mann et al. Apr 2003 B1
6558320 Causey et al. May 2003 B1
6558351 Steil et al. May 2003 B1
6565509 Say et al. May 2003 B1
6567416 Chuah May 2003 B1
6571294 Simmon et al. May 2003 B2
6572542 Houben et al. Jun 2003 B1
6572545 Knobbe et al. Jun 2003 B2
6578002 Derzay et al. Jun 2003 B1
6581117 Klein et al. Jun 2003 B1
6587034 Heiman et al. Jul 2003 B1
6589229 Connelly et al. Jul 2003 B1
6599281 Struys et al. Jul 2003 B1
6602191 Quy Aug 2003 B2
6605072 Struys et al. Aug 2003 B2
6628809 Rowe et al. Sep 2003 B1
6631353 Davis et al. Oct 2003 B1
6640246 Gardy, Jr. et al. Oct 2003 B1
6641533 Causey, III et al. Nov 2003 B2
6647299 Bourget Nov 2003 B2
6652455 Kocher Nov 2003 B1
6653937 Nelson et al. Nov 2003 B2
6659947 Carter et al. Dec 2003 B1
6669630 Joliat et al. Dec 2003 B1
6671563 Engleson et al. Dec 2003 B1
6673033 Sciulli et al. Jan 2004 B1
6674403 Gray et al. Jan 2004 B2
6681003 Linder et al. Jan 2004 B2
6689091 Bui et al. Feb 2004 B2
6692241 Watanabe et al. Feb 2004 B2
6694191 Starkweather et al. Feb 2004 B2
6694334 DuLong et al. Feb 2004 B2
6721286 Williams et al. Apr 2004 B1
6721582 Trepagnier et al. Apr 2004 B2
6725200 Rost Apr 2004 B1
6731989 Engleson et al. May 2004 B2
6740072 Starkweather et al. May 2004 B2
6751651 Crockett Jun 2004 B2
6752787 Causey, III et al. Jun 2004 B1
6753830 Gelbman Jun 2004 B2
6758810 Lebel et al. Jul 2004 B2
6773396 Flach et al. Aug 2004 B2
6774786 Havekost et al. Aug 2004 B1
6775577 Cmkovich et al. Aug 2004 B2
6780156 Haueter et al. Aug 2004 B2
6790198 White et al. Sep 2004 B1
6796956 Hartlaub et al. Sep 2004 B2
6799149 Hartlaub Sep 2004 B2
6809653 Mann et al. Oct 2004 B1
6811534 Bowman, IV et al. Nov 2004 B2
6816605 Rowe et al. Nov 2004 B2
6839753 Biondi et al. Jan 2005 B2
6852104 Blomquist Feb 2005 B2
6859134 Heiman et al. Feb 2005 B1
6871211 Labounty et al. Mar 2005 B2
6873268 Lebel et al. Mar 2005 B2
6876303 Reeder et al. Apr 2005 B2
6885881 Leonhardt Apr 2005 B2
6891525 Ogoro May 2005 B2
6892278 Ebergen May 2005 B2
6899695 Herrera May 2005 B2
6915170 Engleson et al. Jul 2005 B2
6923763 Kovatchev et al. Aug 2005 B1
6924781 Gelbman Aug 2005 B1
6928338 Buchser et al. Aug 2005 B1
6936029 Mann et al. Aug 2005 B2
6945954 Hochman et al. Sep 2005 B2
6948492 Wemeling et al. Sep 2005 B2
6958677 Carter Oct 2005 B1
6958691 Anderson et al. Oct 2005 B1
6958705 Lebel et al. Oct 2005 B2
6961448 Nichols et al. Nov 2005 B2
6969352 Chiang et al. Nov 2005 B2
6969865 Duchon et al. Nov 2005 B2
6974437 Lebel et al. Dec 2005 B2
6979326 Mann et al. Dec 2005 B2
6980958 Surwit et al. Dec 2005 B1
6985870 Martucci et al. Jan 2006 B2
6986347 Hickle Jan 2006 B2
6997880 Carlebach et al. Feb 2006 B2
6997920 Mann et al. Feb 2006 B2
6998984 Zittrain Feb 2006 B1
7017293 Riley Mar 2006 B2
7025743 Mann et al. Apr 2006 B2
7029455 Flaherty Apr 2006 B2
7038584 Carter May 2006 B2
7060031 Webb et al. Jun 2006 B2
7060059 Keith et al. Jun 2006 B2
7069552 Lindberg et al. Jun 2006 B2
7072725 Bristol et al. Jul 2006 B2
7079035 Bock et al. Jul 2006 B2
7092943 Roese et al. Aug 2006 B2
7096072 Engleson et al. Aug 2006 B2
7099809 Dori Aug 2006 B2
7103419 Engleson et al. Sep 2006 B2
7103578 Beck et al. Sep 2006 B2
7107106 Engleson et al. Sep 2006 B2
7108680 Rohr et al. Sep 2006 B2
7109878 Mann et al. Sep 2006 B2
7117041 Engleson et al. Oct 2006 B2
7136645 Hanson et al. Nov 2006 B2
7137964 Flaherty Nov 2006 B2
7142190 Martinez Nov 2006 B2
7150741 Erickson et al. Dec 2006 B2
7153289 Vasko Dec 2006 B2
7154397 Zerhusen et al. Dec 2006 B2
7156807 Carter et al. Jan 2007 B2
7161484 Tsoukalis et al. Jan 2007 B2
7167755 Seeberger et al. Jan 2007 B2
7167920 Traversat Jan 2007 B2
7171277 Engleson et al. Jan 2007 B2
7171492 Borella et al. Jan 2007 B1
7181493 English et al. Feb 2007 B2
7185288 McKeever Feb 2007 B2
7193514 Ritson Mar 2007 B2
7197025 Chuah Mar 2007 B2
7201734 Hickle Apr 2007 B2
7204823 Estes et al. Apr 2007 B2
7213009 Pestotnik May 2007 B2
7216802 de la Huerga May 2007 B1
7220240 Struys et al. May 2007 B2
7224979 Singhal et al. May 2007 B2
7229430 Hickle et al. Jun 2007 B2
7230529 Ketcherside Jun 2007 B2
7236936 White et al. Jun 2007 B2
7238164 Childers et al. Jul 2007 B2
7247154 Hickle Jul 2007 B2
7248239 Dowling Jul 2007 B2
7250856 Havekost et al. Jul 2007 B2
7255683 Vanderveen et al. Aug 2007 B2
7256888 Staehr Aug 2007 B2
7258534 Fathallah et al. Aug 2007 B2
7263213 Rowe Aug 2007 B2
7267664 Rizzo Sep 2007 B2
7267665 Steil et al. Sep 2007 B2
7275156 Balfanz et al. Sep 2007 B2
7278983 Ireland et al. Oct 2007 B2
7289815 Gfeller et al. Oct 2007 B2
7289948 Mohri Oct 2007 B1
7293107 Hanson et al. Nov 2007 B1
7295119 Rappaport et al. Nov 2007 B2
7295556 Roese et al. Nov 2007 B2
7301451 Hastings Nov 2007 B2
7308300 Toews et al. Dec 2007 B2
7315825 Rosenfeld et al. Jan 2008 B2
7319386 Collins, Jr. et al. Jan 2008 B2
7324000 Zittrain et al. Jan 2008 B2
7327705 Fletcher et al. Feb 2008 B2
7343224 DiGianfilippo et al. Mar 2008 B2
7346025 Bryson Mar 2008 B2
7347836 Peterson et al. Mar 2008 B2
7354420 Steil et al. Apr 2008 B2
7369897 Boveja et al. May 2008 B2
7369948 Ferenczi et al. May 2008 B1
7383088 Spinelli et al. Jun 2008 B2
7384410 Eggers et al. Jun 2008 B2
7398183 Holland et al. Jul 2008 B2
7398279 Muno, Jr. et al. Jul 2008 B2
7399277 Saidara et al. Jul 2008 B2
7402153 Steil et al. Jul 2008 B2
7420472 Tran Sep 2008 B2
7432807 Schmitt Oct 2008 B2
7447643 Olson Nov 2008 B1
7454314 Holland et al. Nov 2008 B2
7457804 Uber, III et al. Nov 2008 B2
7464040 Joao Dec 2008 B2
7471994 Ford et al. Dec 2008 B2
7483756 Engleson et al. Jan 2009 B2
7489808 Gerder Feb 2009 B2
7490021 Holland et al. Feb 2009 B2
7490048 Joao Feb 2009 B2
7491187 Van Den Berghe et al. Feb 2009 B2
7519905 Kougiouris Apr 2009 B2
7523401 Aldridge Apr 2009 B1
7524304 Genosar Apr 2009 B2
7551078 Carlson Jun 2009 B2
7559321 Wermeling et al. Jul 2009 B2
7565197 Haulbrich et al. Jul 2009 B2
7572230 Neumann et al. Aug 2009 B2
7578802 Hickle Aug 2009 B2
7621009 Elhabashy Nov 2009 B2
D606533 De Jong et al. Dec 2009 S
7636718 Steen et al. Dec 2009 B1
7640172 Kuth Dec 2009 B2
7645258 White et al. Jan 2010 B2
7647237 Malave et al. Jan 2010 B2
7662124 Duchon et al. Feb 2010 B2
7668731 Martucci et al. Feb 2010 B2
7671733 McNeal et al. Mar 2010 B2
7678071 Lebel et al. Mar 2010 B2
7687678 Jacobs Mar 2010 B2
7697994 VanDanacker et al. Apr 2010 B2
7698239 Lieuallen Apr 2010 B2
7705727 Pestotnik Apr 2010 B2
7724147 Brown et al. May 2010 B2
7739126 Cave Jun 2010 B1
7746218 Collins, Jr. Jun 2010 B2
7766873 Moberg et al. Aug 2010 B2
7776029 Whitehurst et al. Aug 2010 B2
7776031 Hartlaub et al. Aug 2010 B2
7785313 Mastrototaro Aug 2010 B2
7806852 Jurson Oct 2010 B1
7806886 Kanderian, Jr. et al. Oct 2010 B2
7826981 Goode, Jr. et al. Nov 2010 B2
7835927 Schlotterbeck et al. Nov 2010 B2
7836314 Chieu Nov 2010 B2
7856276 Ripart et al. Dec 2010 B2
7860583 Condurso et al. Dec 2010 B2
7868754 Salvat, Jr. Jan 2011 B2
7871394 Halbert et al. Jan 2011 B2
7886231 Hopermann et al. Feb 2011 B2
7895053 Holland et al. Feb 2011 B2
7896842 Palmroos et al. Mar 2011 B2
7899546 Sieracki et al. Mar 2011 B2
7905710 Wang et al. Mar 2011 B2
7920061 Klein et al. Apr 2011 B2
7933780 de la Huerga Apr 2011 B2
7938796 Moubayed May 2011 B2
7945452 Fathallah et al. May 2011 B2
7974714 Hoffberg Jul 2011 B2
7996241 Zak Aug 2011 B2
8034026 Grant Oct 2011 B2
8038593 Friedman et al. Oct 2011 B2
8048040 Kiani Nov 2011 B2
8060576 Chan et al. Nov 2011 B2
8065161 Howard et al. Nov 2011 B2
8066672 Mandro Nov 2011 B2
8078983 Davis et al. Dec 2011 B2
8082018 Duchon et al. Dec 2011 B2
8082312 Chan et al. Dec 2011 B2
8147448 Sundar et al. Apr 2012 B2
8149131 Blornquist Apr 2012 B2
8169914 Bajpai May 2012 B2
8171094 Chan et al. May 2012 B2
8172798 Hungerford et al. May 2012 B2
8185322 Schroeder et al. May 2012 B2
8195478 Petersen et al. Jun 2012 B2
8206350 Mann et al. Jun 2012 B2
8219413 Martinez et al. Jul 2012 B2
8231578 Fathallah et al. Jul 2012 B2
8234128 Martucci et al. Jul 2012 B2
8267892 Spencer et al. Sep 2012 B2
8271106 Wehba et al. Sep 2012 B2
8287495 Michaud et al. Oct 2012 B2
8291337 Gannin et al. Oct 2012 B2
8298184 DiPerna et al. Oct 2012 B2
8352290 Bartz et al. Jan 2013 B2
8359338 Butterfield et al. Jan 2013 B2
8380536 Howard et al. Feb 2013 B2
8387112 Ranjan et al. Feb 2013 B1
8394077 Jacobson et al. Mar 2013 B2
8403908 Jacobson et al. Mar 2013 B2
8435206 Evans et al. May 2013 B2
8449523 Brukalo et al. May 2013 B2
8452953 Buck et al. May 2013 B2
8453645 Figueiredo et al. Jun 2013 B2
8480648 Burnett et al. Jul 2013 B2
8489427 Simpson Jul 2013 B2
8494879 Davis et al. Jul 2013 B2
8504179 Blomquist Aug 2013 B2
8517990 Teel et al. Aug 2013 B2
8518021 Stewart et al. Aug 2013 B2
8543416 Palmroos et al. Sep 2013 B2
8551038 Tsoukalis et al. Oct 2013 B2
8560345 Wehba et al. Oct 2013 B2
8577692 Silkaitis et al. Nov 2013 B2
8579884 Lanier et al. Nov 2013 B2
8626530 Tran et al. Jan 2014 B1
8655676 Wehba et al. Feb 2014 B2
8660860 Wehba et al. Feb 2014 B2
8662388 Belkin Mar 2014 B2
8666769 Butler et al. Mar 2014 B2
8700421 Feng et al. Apr 2014 B2
8731960 Butler et al. May 2014 B2
8768719 Wehba et al. Jul 2014 B2
8771251 Ruchti et al. Jul 2014 B2
8777894 Butterfield et al. Jul 2014 B2
8777895 Hsu et al. Jul 2014 B2
8799012 Butler et al. Aug 2014 B2
8876793 Ledford et al. Nov 2014 B2
8922330 Moberg et al. Dec 2014 B2
8936565 Chawla Jan 2015 B2
8952794 Bloomquist et al. Feb 2015 B2
8998100 Halbert et al. Apr 2015 B2
9026370 Rubalcaba et al. May 2015 B2
9069887 Gupta et al. Jun 2015 B2
9089642 Murphy et al. Jul 2015 B2
9114217 Sur et al. Aug 2015 B2
9123077 Silkaitis et al. Sep 2015 B2
9192712 DeBelser et al. Nov 2015 B2
9240002 Hume et al. Jan 2016 B2
9381296 Arrizza et al. Jul 2016 B2
9393362 Cozmi et al. Jul 2016 B2
9498583 Sur et al. Nov 2016 B2
9539383 Kohlbrecher Jan 2017 B2
9572923 Howard et al. Feb 2017 B2
9594875 Arrizza et al. Mar 2017 B2
9604000 Wehba et al. Mar 2017 B2
9641432 Jha et al. May 2017 B2
9649431 Gray et al. May 2017 B2
9662436 Belkin et al. May 2017 B2
9690909 Stewart et al. Jun 2017 B2
9707341 Dumas, III et al. Jul 2017 B2
9724470 Day et al. Aug 2017 B2
9764082 Day et al. Sep 2017 B2
9971871 Arrizza et al. May 2018 B2
9995611 Ruchti et al. Jun 2018 B2
10022498 Ruchti et al. Jul 2018 B2
10042986 Ruchti et al. Aug 2018 B2
10046112 Oruklu et al. Aug 2018 B2
10166328 Oruklu et al. Jan 2019 B2
10238799 Kohlbrecher Mar 2019 B2
10238801 Wehba et al. Mar 2019 B2
10242060 Butler et al. Mar 2019 B2
10300194 Day et al. May 2019 B2
10311972 Kohlbrecher et al. Jun 2019 B2
10314974 Day et al. Jun 2019 B2
10333843 Jha et al. Jun 2019 B2
10430761 Hume et al. Oct 2019 B2
10434246 Silkaitis et al. Oct 2019 B2
10463788 Day Nov 2019 B2
20010016056 Westphal et al. Aug 2001 A1
20010031944 Peterson et al. Oct 2001 A1
20010032099 Joao Oct 2001 A1
20010037060 Thompson et al. Nov 2001 A1
20010044731 Coffman et al. Nov 2001 A1
20010048027 Walsh Dec 2001 A1
20010051787 Haller et al. Dec 2001 A1
20010056358 Dulong et al. Dec 2001 A1
20020010595 Kapp Jan 2002 A1
20020013551 Zaitsu Jan 2002 A1
20020013723 Mise Jan 2002 A1
20020015018 Shimazu et al. Feb 2002 A1
20020019584 Schulze et al. Feb 2002 A1
20020026103 Norris et al. Feb 2002 A1
20020029776 Blomquist Mar 2002 A1
20020032583 Joao Mar 2002 A1
20020038392 de la Huerga Mar 2002 A1
20020040208 Flaherty et al. Apr 2002 A1
20020040282 Bailey et al. Apr 2002 A1
20020082728 Mueller et al. Jun 2002 A1
20020087115 Hartlaub Jul 2002 A1
20020087116 Hartlaub Jul 2002 A1
20020095486 Bahl Jul 2002 A1
20020103675 Vanelli Aug 2002 A1
20020123905 Goodroe et al. Sep 2002 A1
20020143580 Bristol et al. Oct 2002 A1
20020152239 Bautista-Lloyd et al. Oct 2002 A1
20020169636 Eggers et al. Nov 2002 A1
20020173702 Lebel et al. Nov 2002 A1
20020173875 Wallace et al. Nov 2002 A1
20020194329 Alling Dec 2002 A1
20030009244 Engleson Jan 2003 A1
20030013959 Grunwald et al. Jan 2003 A1
20030014222 Klass et al. Jan 2003 A1
20030014817 Gallant et al. Jan 2003 A1
20030025602 Medema et al. Feb 2003 A1
20030028082 Thompson Feb 2003 A1
20030036683 Kehr et al. Feb 2003 A1
20030047126 Tomaschko Mar 2003 A1
20030050621 Lebel et al. Mar 2003 A1
20030059750 Bindler et al. Mar 2003 A1
20030060688 Ciarniello et al. Mar 2003 A1
20030069963 Jayant et al. Apr 2003 A1
20030079746 Hickle May 2003 A1
20030097529 Arimilli et al. May 2003 A1
20030104982 Wittmann et al. Jun 2003 A1
20030106553 Vanderveen Jun 2003 A1
20030115358 Yun Jun 2003 A1
20030120384 Haitin et al. Jun 2003 A1
20030125662 Bui Jul 2003 A1
20030130616 Steil Jul 2003 A1
20030135087 Hickle et al. Jul 2003 A1
20030139701 White et al. Jul 2003 A1
20030140928 Bui et al. Jul 2003 A1
20030140929 Wilkes et al. Jul 2003 A1
20030141981 Bui et al. Jul 2003 A1
20030143746 Sage, Jr. Jul 2003 A1
20030144878 Wilkes et al. Jul 2003 A1
20030158749 Olchanski et al. Aug 2003 A1
20030187338 Say et al. Oct 2003 A1
20030200116 Forrester Oct 2003 A1
20030204416 Acharya Oct 2003 A1
20030204781 Peebles et al. Oct 2003 A1
20030212364 Mann et al. Nov 2003 A1
20030212379 Bylund et al. Nov 2003 A1
20030212821 Gillies et al. Nov 2003 A1
20030217962 Childers et al. Nov 2003 A1
20040015132 Brown Jan 2004 A1
20040019607 Moubayed et al. Jan 2004 A1
20040030323 Ullestad et al. Feb 2004 A1
20040039257 Hickle Feb 2004 A1
20040057226 Berthou et al. Mar 2004 A1
20040064341 Langan et al. Apr 2004 A1
20040064342 Browne et al. Apr 2004 A1
20040064435 Moubayed et al. Apr 2004 A1
20040073811 Sanin Apr 2004 A1
20040077934 Massad Apr 2004 A1
20040078231 Wilkes et al. Apr 2004 A1
20040078236 Stoodley et al. Apr 2004 A1
20040104271 Martucci et al. Jun 2004 A1
20040122530 Hansen Jun 2004 A1
20040128162 Schlotterbeck et al. Jul 2004 A1
20040128163 Goodman et al. Jul 2004 A1
20040133441 Brady et al. Jul 2004 A1
20040139004 Cohen et al. Jul 2004 A1
20040145480 Despotis Jul 2004 A1
20040147034 Gore et al. Jul 2004 A1
20040167464 Ireland et al. Aug 2004 A1
20040167465 Kohler Aug 2004 A1
20040167804 Simpson Aug 2004 A1
20040172222 Simpson et al. Sep 2004 A1
20040172283 Vanderveen Sep 2004 A1
20040172301 Mihai et al. Sep 2004 A1
20040172302 Martucci et al. Sep 2004 A1
20040176667 Mihai et al. Sep 2004 A1
20040176980 Bulitta et al. Sep 2004 A1
20040176984 White et al. Sep 2004 A1
20040181314 Zaleski Sep 2004 A1
20040189708 Larcheveque et al. Sep 2004 A1
20040193325 Bonderud Sep 2004 A1
20040193328 Butterfield et al. Sep 2004 A1
20040193453 Butterfield et al. Sep 2004 A1
20040204673 Flaherty et al. Oct 2004 A1
20040215278 Stegink et al. Oct 2004 A1
20040220517 Starkweather et al. Nov 2004 A1
20040225252 Gillespie et al. Nov 2004 A1
20040236240 Kraus et al. Nov 2004 A1
20040243438 Mintz Dec 2004 A1
20040254434 Goodnow et al. Dec 2004 A1
20050010269 Lebel et al. Jan 2005 A1
20050020886 Hutchinson et al. Jan 2005 A1
20050021006 Tonnies Jan 2005 A1
20050027560 Cook Feb 2005 A1
20050027567 Taha Feb 2005 A1
20050038311 Kuth Feb 2005 A1
20050038669 Sachdeva et al. Feb 2005 A1
20050038680 McMahon Feb 2005 A1
20050040226 Al-Sheikh Feb 2005 A1
20050043620 Fallows et al. Feb 2005 A1
20050049910 Lancaster et al. Mar 2005 A1
20050055242 Bello et al. Mar 2005 A1
20050055244 Mullan et al. Mar 2005 A1
20050065465 Lebel et al. Mar 2005 A1
20050065817 Mihai et al. Mar 2005 A1
20050075544 Shapiro et al. Apr 2005 A1
20050080801 Kothandaraman et al. Apr 2005 A1
20050086071 Fox, Jr. et al. Apr 2005 A1
20050086072 Fox Apr 2005 A1
20050090808 Malave et al. Apr 2005 A1
20050099624 Staehr May 2005 A1
20050102162 Blumenfeld May 2005 A1
20050102165 Oshita et al. May 2005 A1
20050102167 Kapoor May 2005 A1
20050102669 Marney et al. May 2005 A1
20050107923 Vanderveen May 2005 A1
20050108057 Cohen May 2005 A1
20050117529 Ramos-Escano Jun 2005 A1
20050119788 Engleson et al. Jun 2005 A1
20050119914 Batch Jun 2005 A1
20050131739 Rabinowitz et al. Jun 2005 A1
20050137522 Aoki Jun 2005 A1
20050137573 McLaughlin Jun 2005 A1
20050154769 Eckart et al. Jul 2005 A1
20050160057 Wefers et al. Jul 2005 A1
20050171503 Van Den Berghe et al. Aug 2005 A1
20050171815 Vanderveen Aug 2005 A1
20050177096 Bollish et al. Aug 2005 A1
20050177395 Blomquist Aug 2005 A1
20050182306 Sloan Aug 2005 A1
20050182355 Bui Aug 2005 A1
20050187950 Parker Aug 2005 A1
20050192557 Brauker et al. Sep 2005 A1
20050197554 Polcha Sep 2005 A1
20050197621 Poulsen et al. Sep 2005 A1
20050210037 Wefers et al. Sep 2005 A1
20050216479 Wefers et al. Sep 2005 A1
20050216480 Wefers et al. Sep 2005 A1
20050223045 Funahashi et al. Oct 2005 A1
20050224083 Crass Oct 2005 A1
20050234746 Funahashi Oct 2005 A1
20050240305 Bogash et al. Oct 2005 A1
20050246416 Blomquist Nov 2005 A1
20050251418 Fox, Jr. et al. Nov 2005 A1
20050273059 Mernoe et al. Dec 2005 A1
20050277873 Stewart et al. Dec 2005 A1
20050277890 Stewart et al. Dec 2005 A1
20050277911 Stewart et al. Dec 2005 A1
20050278194 Holland et al. Dec 2005 A1
20060004772 Hagan et al. Jan 2006 A1
20060009727 O'Mahony et al. Jan 2006 A1
20060009734 Martin Jan 2006 A1
20060010098 Goodnow et al. Jan 2006 A1
20060042139 Mendes Mar 2006 A1
20060047270 Shelton Mar 2006 A1
20060053036 Coffman et al. Mar 2006 A1
20060064020 Burnes et al. Mar 2006 A1
20060074633 Mahesh et al. Apr 2006 A1
20060074920 Wefers et al. Apr 2006 A1
20060079831 Gilbert Apr 2006 A1
20060089854 Holland et al. Apr 2006 A1
20060089855 Holland et al. Apr 2006 A1
20060100746 Leibner-Druska May 2006 A1
20060100907 Holland et al. May 2006 A1
20060106649 Eggers et al. May 2006 A1
20060111943 Wu May 2006 A1
20060116904 Brem Jun 2006 A1
20060116907 Rhodes et al. Jun 2006 A1
20060122481 Sievenpiper et al. Jun 2006 A1
20060122867 Eggers et al. Jun 2006 A1
20060129429 Moubayed et al. Jun 2006 A1
20060129434 Smitherman et al. Jun 2006 A1
20060129435 Smitherman et al. Jun 2006 A1
20060136266 Tarassenko et al. Jun 2006 A1
20060136271 Eggers et al. Jun 2006 A1
20060143051 Eggers et al. Jun 2006 A1
20060173260 Gaoni et al. Aug 2006 A1
20060173406 Hayes et al. Aug 2006 A1
20060173715 Wang et al. Aug 2006 A1
20060173927 Beyer et al. Aug 2006 A1
20060190302 Eggers et al. Aug 2006 A1
20060195022 Trepagnier et al. Aug 2006 A1
20060200007 Brockway et al. Sep 2006 A1
20060200369 Batch et al. Sep 2006 A1
20060211404 Cromp et al. Sep 2006 A1
20060224141 Rush et al. Oct 2006 A1
20060229918 Fotsch et al. Oct 2006 A1
20060258985 Russell Nov 2006 A1
20060259327 Hoag Nov 2006 A1
20060264895 Flanders Nov 2006 A1
20060265246 Hoag Nov 2006 A1
20060267753 Hussey et al. Nov 2006 A1
20060268710 Appanna et al. Nov 2006 A1
20060277206 Bailey et al. Dec 2006 A1
20060287885 Frick Dec 2006 A1
20070015972 Wang et al. Jan 2007 A1
20070016443 Wachman et al. Jan 2007 A1
20070027506 Stender et al. Feb 2007 A1
20070060796 Kim Mar 2007 A1
20070060870 Tolle et al. Mar 2007 A1
20070060871 Istoc Mar 2007 A1
20070061393 Moore Mar 2007 A1
20070065363 Dalal et al. Mar 2007 A1
20070073419 Sesay Mar 2007 A1
20070078314 Grounsell Apr 2007 A1
20070083870 Kanakogi Apr 2007 A1
20070088333 Levin et al. Apr 2007 A1
20070093786 Goldsmith et al. Apr 2007 A1
20070100665 Brown May 2007 A1
20070100667 Bardy May 2007 A1
20070106126 Mannheimer et al. May 2007 A1
20070112298 Mueller et al. May 2007 A1
20070116037 Moore May 2007 A1
20070118405 Campbell et al. May 2007 A1
20070135866 Baker Jun 2007 A1
20070136098 Smythe et al. Jun 2007 A1
20070142822 Remde Jun 2007 A1
20070156282 Dunn Jul 2007 A1
20070156452 Batch Jul 2007 A1
20070169008 Varanasi et al. Jul 2007 A1
20070179448 Lim et al. Aug 2007 A1
20070186923 Poutiatine et al. Aug 2007 A1
20070191817 Martin Aug 2007 A1
20070191973 Holzbauer et al. Aug 2007 A1
20070213657 Jennewine et al. Sep 2007 A1
20070214003 Holland et al. Sep 2007 A1
20070215545 Bissler et al. Sep 2007 A1
20070232867 Hansmann Oct 2007 A1
20070233035 Wehba et al. Oct 2007 A1
20070233049 Wehba et al. Oct 2007 A1
20070233206 Frikart Oct 2007 A1
20070233520 Wehba et al. Oct 2007 A1
20070251835 Mehta et al. Nov 2007 A1
20070253021 Mehta et al. Nov 2007 A1
20070254593 Jollota et al. Nov 2007 A1
20070255125 Moberg et al. Nov 2007 A1
20070257788 Carlson Nov 2007 A1
20070258395 Jollota et al. Nov 2007 A1
20070299687 Palmer et al. Dec 2007 A1
20070299695 Jung et al. Dec 2007 A1
20080004904 Tran Jan 2008 A1
20080009684 Corsetti et al. Jan 2008 A1
20080033361 Evans et al. Feb 2008 A1
20080034323 Blomquist Feb 2008 A1
20080041942 Aissa Feb 2008 A1
20080052704 Wysocki Feb 2008 A1
20080065007 Peterson et al. Mar 2008 A1
20080065417 Jung et al. Mar 2008 A1
20080071217 Moubayed et al. Mar 2008 A1
20080071251 Moubayed et al. Mar 2008 A1
20080091466 Butler et al. Apr 2008 A1
20080095339 Elliott Apr 2008 A1
20080097289 Steil et al. Apr 2008 A1
20080126969 Blomquist May 2008 A1
20080139907 Rao et al. Jun 2008 A1
20080149117 Raghuram Jun 2008 A1
20080154177 Moubayed et al. Jun 2008 A1
20080172337 Banfield et al. Jul 2008 A1
20080184219 Matsumoto Jul 2008 A1
20080188796 Steil et al. Aug 2008 A1
20080214919 Harmon et al. Sep 2008 A1
20080246748 Cassidy et al. Oct 2008 A1
20080256305 Kwon Oct 2008 A1
20080262469 Bristol et al. Oct 2008 A1
20080269714 Mastrototaro et al. Oct 2008 A1
20080269723 Mastrototaro et al. Oct 2008 A1
20080275384 Mastrototaro et al. Nov 2008 A1
20080300572 Rankers et al. Dec 2008 A1
20080320387 Sasaki et al. Dec 2008 A1
20080320466 Dias Dec 2008 A1
20090005703 Fasciano Jan 2009 A1
20090005728 Weinert et al. Jan 2009 A1
20090006061 Thukral et al. Jan 2009 A1
20090006129 Thukral Jan 2009 A1
20090006133 Weinert Jan 2009 A1
20090018495 Panduro Jan 2009 A1
20090051560 Manning et al. Feb 2009 A1
20090054743 Stewart Feb 2009 A1
20090054754 McMahon et al. Feb 2009 A1
20090057399 Sajkowsky Mar 2009 A1
20090069785 Miller et al. Mar 2009 A1
20090099867 Newman Apr 2009 A1
20090135196 Holland et al. May 2009 A1
20090143662 Estes et al. Jun 2009 A1
20090149743 Barron et al. Jun 2009 A1
20090150174 Buck et al. Jun 2009 A1
20090150878 Pathak et al. Jun 2009 A1
20090156991 Roberts Jun 2009 A1
20090157695 Roberts Jun 2009 A1
20090158274 Roberts Jun 2009 A1
20090177146 Nesbitt et al. Jul 2009 A1
20090177769 Roberts Jul 2009 A1
20090177992 Rubalcaba et al. Jul 2009 A1
20090183147 Davis et al. Jul 2009 A1
20090209938 Aalto-Setala Aug 2009 A1
20090210250 Prax et al. Aug 2009 A1
20090221890 Saffer et al. Sep 2009 A1
20090231249 Wang et al. Sep 2009 A1
20090270833 DeBelser Oct 2009 A1
20090275886 Bloomquist et al. Nov 2009 A1
20090275896 Kamen et al. Nov 2009 A1
20090284691 Marhefka et al. Nov 2009 A1
20090326340 Wang Dec 2009 A1
20090326516 Bangera et al. Dec 2009 A1
20100022988 Wochner Jan 2010 A1
20100036310 Hillman Feb 2010 A1
20100056992 Hayter Mar 2010 A1
20100095229 Dixon et al. Apr 2010 A1
20100121170 Rule May 2010 A1
20100121415 Skelton et al. May 2010 A1
20100121654 Portnoy et al. May 2010 A1
20100121752 Banigan et al. May 2010 A1
20100130933 Holland et al. May 2010 A1
20100131434 Magent et al. May 2010 A1
20100138523 Umess et al. Jun 2010 A1
20100146137 Wu et al. Jun 2010 A1
20100156633 Buck et al. Jun 2010 A1
20100160854 Gauthier Jun 2010 A1
20100160860 Celentano et al. Jun 2010 A1
20100174266 Estes Jul 2010 A1
20100191525 Rabenko et al. Jul 2010 A1
20100198034 Thomas et al. Aug 2010 A1
20100198196 Wei Aug 2010 A1
20100200506 Ware et al. Aug 2010 A1
20100209268 Davis Aug 2010 A1
20100212675 Walling et al. Aug 2010 A1
20100217621 Schoenberg Aug 2010 A1
20100234708 Buck et al. Sep 2010 A1
20100250732 Bucknell Sep 2010 A1
20100271479 Heydlauf Oct 2010 A1
20100273738 Valcke et al. Oct 2010 A1
20100280486 Khair et al. Nov 2010 A1
20100292634 Kircher Nov 2010 A1
20100298765 Budiman et al. Nov 2010 A1
20100318025 John Dec 2010 A1
20110001605 Kiani et al. Jan 2011 A1
20110040158 Katz et al. Feb 2011 A1
20110060758 Schlotterbeck et al. Mar 2011 A1
20110071844 Cannon et al. Mar 2011 A1
20110072379 Gannon Mar 2011 A1
20110078608 Gannon et al. Mar 2011 A1
20110093284 Dicks et al. Apr 2011 A1
20110099313 Bolanowski Apr 2011 A1
20110125095 Lebel et al. May 2011 A1
20110138185 Ju et al. Jun 2011 A1
20110175728 Baker, Jr. Jul 2011 A1
20110178462 Moberg et al. Jul 2011 A1
20110196748 Caron et al. Aug 2011 A1
20110231216 Fyke et al. Sep 2011 A1
20110257496 Terashima et al. Oct 2011 A1
20110257798 Ali et al. Oct 2011 A1
20110259954 Bartz et al. Oct 2011 A1
20110264043 Kotnick et al. Oct 2011 A1
20110264044 Bartz et al. Oct 2011 A1
20110266221 Ware et al. Nov 2011 A1
20110270045 Lebel et al. Nov 2011 A1
20110275904 Lebel et al. Nov 2011 A1
20110286457 Ee Nov 2011 A1
20110289497 Kiaie et al. Nov 2011 A1
20110295196 Chazot et al. Dec 2011 A1
20110295341 Estes et al. Dec 2011 A1
20110296051 Vange Dec 2011 A1
20110296411 Tang et al. Dec 2011 A1
20110313789 Karmen et al. Dec 2011 A1
20110319813 Kamen et al. Dec 2011 A1
20110320049 Chossat et al. Dec 2011 A1
20120005680 Dolby et al. Jan 2012 A1
20120011253 Friedman et al. Jan 2012 A1
20120016305 Jollota Jan 2012 A1
20120029941 Malave et al. Feb 2012 A1
20120070045 Vesper et al. Mar 2012 A1
20120095437 Hemmerling Apr 2012 A1
20120112903 Kaib et al. May 2012 A1
20120130198 Beaule May 2012 A1
20120143116 Ware et al. Jun 2012 A1
20120150556 Galasso et al. Jun 2012 A1
20120157920 Flachbart et al. Jun 2012 A1
20120179135 Rinehart et al. Jul 2012 A1
20120179136 Rinehart et al. Jul 2012 A1
20120203177 Lanier Aug 2012 A1
20120245554 Kawamura Sep 2012 A1
20120259978 Petersen et al. Oct 2012 A1
20120277716 Ali et al. Nov 2012 A1
20120284734 McQuaid et al. Nov 2012 A1
20120323212 Murphy Dec 2012 A1
20130006666 Schneider Jan 2013 A1
20130006702 Wu Jan 2013 A1
20130012877 Debelser et al. Jan 2013 A1
20130012880 Blomquist Jan 2013 A1
20130015980 Evans et al. Jan 2013 A1
20130036403 Geist Feb 2013 A1
20130036412 Birtwhistle et al. Feb 2013 A1
20130066265 Grant Mar 2013 A1
20130072872 Yodfat et al. Mar 2013 A1
20130096444 Condurso et al. Apr 2013 A1
20130096648 Benson Apr 2013 A1
20130102963 Marsh et al. Apr 2013 A1
20130138452 Cork et al. May 2013 A1
20130144206 Lee et al. Jun 2013 A1
20130167245 Birtwhistle et al. Jun 2013 A1
20130191770 Bartz et al. Jul 2013 A1
20130204188 Kamen et al. Aug 2013 A1
20130218080 Peterfreund et al. Aug 2013 A1
20130274669 Stempfle et al. Oct 2013 A1
20130275539 Gross et al. Oct 2013 A1
20130291116 Homer Oct 2013 A1
20130296823 Melker et al. Nov 2013 A1
20130296984 Burnett et al. Nov 2013 A1
20130317753 Kamen et al. Nov 2013 A1
20130346108 Kamen et al. Dec 2013 A1
20140039446 Day Feb 2014 A1
20140163517 Finan et al. Jun 2014 A1
20140180711 Kamen et al. Jun 2014 A1
20140257251 Bush et al. Sep 2014 A1
20140266790 Al-Ali et al. Sep 2014 A1
20140269643 Sun Sep 2014 A1
20140288947 Simpson et al. Sep 2014 A1
20140297329 Rock Oct 2014 A1
20140366878 Baron Dec 2014 A1
20150005935 Bae et al. Jan 2015 A1
20150066531 Jacobson et al. Mar 2015 A1
20150100038 McCann et al. Apr 2015 A1
20150134265 Kohlbrecher et al. May 2015 A1
20150151051 Tsoukalis Jun 2015 A1
20150379237 Mills et al. Dec 2015 A1
20160015885 Pananen et al. Jan 2016 A1
20160034655 Gray et al. Feb 2016 A1
20160051749 Istoc Feb 2016 A1
20160051751 Silkaitis et al. Feb 2016 A1
20160103960 Hume et al. Apr 2016 A1
20160228633 Welsch et al. Aug 2016 A1
20160350513 Jacobson et al. Dec 2016 A1
20170262590 Karakosta et al. Sep 2017 A1
20170286637 Arrizza et al. Oct 2017 A1
20170319780 Belkin et al. Nov 2017 A1
20170331735 Jha et al. Nov 2017 A1
20180028742 Day et al. Feb 2018 A1
20180043094 Day et al. Feb 2018 A1
20180121613 Connely, IV et al. May 2018 A1
20180181712 Ensey et al. Jun 2018 A1
20190096518 Pace Mar 2019 A1
20190147998 Ruchti et al. May 2019 A1
20190228863 Dharwad et al. Jul 2019 A1
20190240405 Wehba et al. Aug 2019 A1
20190243829 Butler et al. Aug 2019 A1
20190269852 Kohlbrecher Sep 2019 A1
20190311803 Kohlbrecher et al. Oct 2019 A1
20200027541 Xavier et al. Jan 2020 A1
20200027542 Xavier et al. Jan 2020 A1
20200027543 Xavier et al. Jan 2020 A1
20200027548 Xavier et al. Jan 2020 A1
20200027549 Xavier et al. Jan 2020 A1
20200027550 Xavier et al. Jan 2020 A1
20200027551 Xavier et al. Jan 2020 A1
20200028837 Xavier et al. Jan 2020 A1
20200028914 Xavier et al. Jan 2020 A1
20200028929 Xavier et al. Jan 2020 A1
20200035346 Xavier et al. Jan 2020 A1
20200035355 Xavier et al. Jan 2020 A1
Foreign Referenced Citations (135)
Number Date Country
2 060 151 Aug 1997 CA
2 125 300 Oct 1999 CA
2 898 825 Jul 2014 CA
01110843 Aug 2003 CO
31 12 762 Jan 1983 DE
34 35 647 Jul 1985 DE
198 44 252 Mar 2000 DE
199 32 147 Jan 2001 DE
103 52 456 Jul 2005 DE
0 319 267 Jun 1989 EP
0 380 061 Aug 1990 EP
0 384 155 Aug 1990 EP
0 460 533 Dec 1991 EP
0 564 127 Jun 1993 EP
0 633 035 Jan 1995 EP
0 652 528 May 1995 EP
0 672 427 Sep 1995 EP
0 683 465 Nov 1995 EP
0 880 936 Dec 1998 EP
1 157 711 Nov 2001 EP
1 174 817 Jan 2002 EP
0 664 102 Apr 2002 EP
1 197 178 Apr 2002 EP
0 830 775 Aug 2002 EP
1 500 025 Apr 2003 EP
2 113 842 Nov 2009 EP
2 228 004 Sep 2010 EP
2 243 506 Oct 2010 EP
2 410 448 Jan 2012 EP
2 742 961 Jun 2014 EP
2 717 919 Sep 1995 FR
2 285 135 Jun 1995 GB
04-161139 Jun 1992 JP
07-502678 Mar 1995 JP
11-500643 Jan 1999 JP
2000-316820 Nov 2000 JP
2002-531154 Sep 2002 JP
2003-016183 Jan 2003 JP
2003-296173 Oct 2003 JP
2005-021463 Jan 2005 JP
2005-527284 Sep 2005 JP
2005-284846 Oct 2005 JP
2006-047319 Feb 2006 JP
2006-520949 Sep 2006 JP
2007-518479 Jul 2007 JP
2007-525256 Sep 2007 JP
2008-080036 Apr 2008 JP
2008-516303 May 2008 JP
2008-158622 Jul 2008 JP
2008-529675 Aug 2008 JP
2009-163534 Jul 2009 JP
2010-502361 Jan 2010 JP
2011-506048 Mar 2011 JP
2012-070991 Apr 2012 JP
2012-523895 Oct 2012 JP
2014-068283 Apr 2014 JP
WO 84001719 May 1984 WO
WO 91016416 Oct 1991 WO
WO 92010985 Jul 1992 WO
WO 92013322 Aug 1992 WO
WO 94005355 Mar 1994 WO
WO 96008755 Mar 1996 WO
WO 96025186 Aug 1996 WO
WO-9625963 Aug 1996 WO
WO 98012670 Mar 1998 WO
WO 98019263 May 1998 WO
WO 99051003 Oct 1999 WO
WO 00013580 Mar 2000 WO
WO 00053243 Sep 2000 WO
WO 01014974 Mar 2001 WO
WO 01033484 May 2001 WO
WO 01045014 Jun 2001 WO
WO 02005702 Jan 2002 WO
WO 02036044 May 2002 WO
WO 02049153 Jun 2002 WO
WO 02049279 Jun 2002 WO
WO 02069099 Sep 2002 WO
WO 02081015 Oct 2002 WO
WO 02088875 Nov 2002 WO
WO 03006091 Jan 2003 WO
WO 03050917 Jun 2003 WO
WO 03091836 Nov 2003 WO
WO 03094092 Nov 2003 WO
WO 2004060455 Jul 2004 WO
WO 2004070557 Aug 2004 WO
WO 2004070562 Aug 2004 WO
WO 2004072828 Aug 2004 WO
WO 2005036447 Apr 2005 WO
WO 2005050526 Jun 2005 WO
WO 2005057175 Jun 2005 WO
WO 2005066872 Jul 2005 WO
WO 2007087443 Aug 2007 WO
WO 2007117705 Oct 2007 WO
WO 2007127879 Nov 2007 WO
WO 2007127880 Nov 2007 WO
WO 2008067245 Jun 2008 WO
WO 2008082854 Jul 2008 WO
WO 2008088490 Jul 2008 WO
WO 2008097316 Aug 2008 WO
WO 2008103915 Aug 2008 WO
WO 2008124478 Oct 2008 WO
WO 2008134146 Nov 2008 WO
WO 2009016504 Feb 2009 WO
WO 2009023406 Feb 2009 WO
WO 2009023407 Feb 2009 WO
WO 2009023634 Feb 2009 WO
WO 2009036327 Mar 2009 WO
WO 2009049252 Apr 2009 WO
WO 2010017279 Feb 2010 WO
WO 2010033919 Mar 2010 WO
WO 2010053703 May 2010 WO
WO 2010075371 Jul 2010 WO
WO 2010099313 Sep 2010 WO
WO 2010114929 Oct 2010 WO
WO 2010119409 Oct 2010 WO
WO 2010124127 Oct 2010 WO
WO 2010130992 Nov 2010 WO
WO 2010135646 Nov 2010 WO
WO 2010135654 Nov 2010 WO
WO 2010135686 Nov 2010 WO
WO 2011005633 Jan 2011 WO
WO 2011022549 Feb 2011 WO
WO 2012048833 Apr 2012 WO
WO 2012049214 Apr 2012 WO
WO 2012049218 Apr 2012 WO
WO 2012120078 Sep 2012 WO
WO 2012140547 Oct 2012 WO
WO 2012164556 Dec 2012 WO
WO 2012170942 Dec 2012 WO
WO 2013045506 Apr 2013 WO
WO 2014100736 Jun 2014 WO
WO 2014131729 Sep 2014 WO
WO 2014131730 Sep 2014 WO
WO 2015124569 Aug 2015 WO
WO 2017176928 Oct 2017 WO
Non-Patent Literature Citations (111)
Entry
McKesson Automation and ALARIS Medical Systems Developing Point-of-Care Bar Coding Solution to Improve IV Medication Safety, Dec. 9, 2002, PR Newswire. (Year: 2002).
Bektas et al., “Bluetooth Communication Employing Antenna Diversity”, Proceedings of Eight IEEE International Symposium on Computers and Communication, Jul. 2003, pp. 6.
Akridge, Jeannie, “New Pumps Outsmart User Error”, Healthcare Purchasing News, Apr. 2011, pp. 10, http://web.archive.org/web/20110426122450/http://www.hpnonline.com/inside/2011-04/1104-OR-Pumps.html.
Alur et al., “Formal Specifications and Analysis of the Computer-Assisted Resuscitation Algorithm (CARA) Infusion Pump Control System”, International Journal on Software Tools for Technology Transfer, Feb. 2004, vol. 5, No. 4, pp. 308-319.
Aragon, Daleen RN, Ph.D., CCRN, “Evaluation of Nursing Work Effort and Perceptions About Blood Glucose Testing in Tight Glycemic Control”, American Journal of Critical Care, Jul. 2006, vol. 15, No. 4, pp. 370-377.
ASHP Advantage, “Improving Medication Safety in Health Systems Through Innovations in Automation Technology”, Proceedings of Educational Symposium and Educational Sessions during the 39th ASHP Midyear Clinical Meeting, Dec. 5-9, 2004, Orlando, FL, pp. 28.
Beard et al., “Total Quality Pain Management: History, Background, Resources”, Abbott Laboratories, TQPM Survey History, available Feb. 2015 or earlier, pp. 1-3.
Bequette, Ph.D., “A Critical Assessment of Algorithms and Challenges in the Development of a Closed-Loop Artificial Pancreas”, Diabetes Technology & Therapeutics, Feb. 28, 2005, vol. 7, No. 1, pp. 28-47.
Bequette, B. Wayne, Ph.D., “Analysis of Algorithms for Intensive Care Unit Blood Glucose Control”, Journal of Diabetes Science and Technology, Nov. 2007, vol. 1, No. 6, pp. 813-824.
Braun, “Infusomat® Space and Accessories”, Instructions for Use, Nov. 2010, pp. 68. http:///corp.bbraun.ee/Extranet/infusioonipumbad/Kasutusiuhendid/Vanad/Kasutusiuhend-Infusomat_Space(vers688J.inglise_k).pdf.
Brownlee, Seth, “Product Spotlight: The Plum A+ with Hospira MedNet Infusion System”, PP&P Magazine, Dec. 2005, vol. 2, No. 7, pp. 2.
Cannon, MD et al., “Automated Heparin-Delivery System to Control Activated Partial Thromboplastin Time”, Circulation, Feb. 16, 1999, vol. 99, pp. 751-756.
Cardinal Health, “Alaris® Syringe Pumps” Technical Service Manual, Copyright 2002-2006, Issue 9, pp. 1-88, http://www.frankshospitalworkshop.com/equipment/documents/infusion_pumps/service_manuals/Cardinal_Alaris_-_Service_Manual.pdf.
“CareAware® Infusion Management”, Cerner Store, as printed May 12, 2011, pp. 3, https://store.cemer.com/items/7.
Chen et al., “Enabling Location-Based Services on Wireless LANs”, The 11th IEEE International Conference on Networks, ICON 2003, Sep. 28-Oct. 1, 2003, pp. 567-572.
“Computer Dictionary”, Microsoft Press, Third Edition, Microsoft Press, 1997, pp. 430 & 506.
Crawford, Anne J., MSN, RNC, “Building a Successful Quality Pain Service: Using Patient Satisfaction Data and the Clinical Practice Guideline”, USA, 1995, pp. 1-6.
Crocker et al., “Augmented BNF for Syntax Specifications: ABNF”, Network Working Group, Standards Track, Jan. 2008, pp. 16.
Davidson et al., “A Computer-Directed Intravenous Insulin System Shown to be Safe, Simple, and Effective in 120,618 h of Operation”, Diabetes Care, Oct. 2005, vol. 28, No. 10, pp. 2418-2423.
Davies, T., “Cordless Data Acquisition in a Hospital Environment”, IEE Colloquium on Cordless Computing—Systems and User Experience, 1993, pp. 4.
Dayhoff et al., “Medical Data Capture and Display: The Importance of Clinicians' Workstation Design”, AMIA, Inc., 1994, pp. 541-545.
Diabetes Close Up, Close Concerns AACE Inpatient Management Conference Report, Consensus Development Conference on Inpatient Diabetes and Metabolic Control, Washington, D.C., Dec. 14-16, 2003, pp. 1-32.
East PhD et al., “Digital Electronic Communication Between ICU Ventilators and Computers and Printers”, Respiratory Care, Sep. 1992, vol. 37, No. 9, pp. 1113-1122.
Einhorn, George W., “Total Quality Pain Management: A Computerized Quality Assessment Tool for Postoperative Pain Management”, Abbott Laboratories, Chicago, IL, Mar. 2, 2000, pp. 1-4.
Eskew et al., “Using Innovative Technologies to Set New Safety Standards for the Infusion of Intravenous Medications”, Hospital Pharmacy, 2002, vol. 37, No. 11, pp. 1179-1189.
Philips, “IntelliSpace Event Management and IntelliVue Patient Monitoring”, Release 10, 2011, http://incenter.medical.philips.com/docllb/enc/fetch/2000/4504/577242/577243/577247/582646/583147/8359175/Philips_Patient_Monitoring_and_IntelliSpace_Event_Management_Interoperability.pdf%3fnodeid%3d8508574%26vemum%3d-2, pp. 2.
Felleiter et al., “Data Processing in Prehospital Emergency Medicine”, International journal of Clinical Monitoring and Computing, Feb. 1995, vol. 12, No. 1, pp. 37-41.
Fogt et al., Development and Evaluation of a Glucose Analyzer for a Glucose-Controlled Insulin Infusion System (Biostator®), Clinical Chemistry, 1978, vol. 24, No. 8, pp. 1366-1372.
Gabel et al., “Camp: A Common API for Measuring Performance”, 21st Large Installations System Administration Conference (LISA '07), 2007, pp. 49-61.
Gage et al., “Automated Anesthesia Surgery Medical Record System”, International Journal of Clinical Monitoring and Computing, Dec. 1990, vol. 7, No. 4, pp. 259-263.
Galt et al., “Personal Digital Assistant-Based Drug Information Sources: Potential to Improve Medication Safety”, Journal of Medical Library Association, Apr. 2005, vol. 93, No. 2, pp. 229-236.
Gardner, Ph.D. et al., “Real Time Data Acquisition: Recommendations for the Medical Information Bus (MIB)”, 1992, pp. 813-817.
“General-Purpose Infusion Pumps”, Health Devices, EXRI Institute, Oct. 1, 2002, vol. 31, No. 10, pp. 353-387.
Givens et al., “Exploring the Internal State of User Interfaces by Combining Computer Vision Techniques with Grammatical Inference”, Proceedings of the 2013 International Conference on Software Engineering, San Francisco, CA, May 18-26, 2013, pp. 1165-1168.
Glaeser, “A Hierarchical Minicomputer System for Continuous Post-Surgical Monitoring”, Computers and Biomedical Research, Aug. 31, 1975, pp. 336-361.
Goldberg et al., “Clinical Results of an Updated Insulin Infusion Protocol in Critically Ill Patients”, Diabetes Spectrum, 2005, vol. 18, No. 3, pp. 188-191.
Gomez et al., “CLAM: Connection-Less, Lightweight, and Multiway Communication Support for Distributed Computing”, Computer Science, 1997, vol. 1199, pp. 227-240.
“GPS Tracker for Medical Equipment”, http://www.trackingsystem.com/forbusinesses/corporate-trackingsystem/1098-gps-tracker-formedicalequipment.html, Mar. 15, 2015, pp. 2.
Graseby, “Model 3000/500 and Micro 3100/505: Volumetric Infusion Pump”, Technical Service Manual, Graseby Medical Ltd., Apr. 2002, Issue A, pp. 160.
Graseby, “Model 3000/500 and Micro 3100/505: Volumetric Infusion Pump: Illustrated Parts List for Pump Serial Nos. from 3000 to 59,999”, Technical Service Manual, Graseby Medical Ltd., Apr. 2002, Issue A, pp. 71.
Halpern et al., “Changes in Critical Care Beds and Occupancy in the United States 1985-2000: Differences Attributable to Hospital Size”, Critical Care Medical, Aug. 2006, vol. 34, No. 8, pp. 2105-2112.
Hamann et al., “PUMPSIM: A Software Package for Simulating Computer-Controlled Drug Infusion Pumps”, Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 1990, vol. 12, No. 5, pp. 2019-2020.
Hasegawa et al., “On a Portable Memory Device for Physical Activities and Informations of Maternal Perception”, Journal of Perinatal Medicine, 1988, vol. 16, No. 4, pp. 349-356.
Hawley et al., “Clinical Implementation of an Automated Medical Information Bus in an Intensive Care Unit”, Proceedings of the Annual Symposium on Computer Application in Medical Care, Nov. 9, 1988, pp. 621-624.
Hayes-Roth et al., “Guardian: A Prototype Intelligent Agent for Intensive-Care Monitoring”, Artificial Intelligence in Medicine, vol. 4, Dec. 31, 1992, pp. 165-185.
Hospira, GemStar® Pain Management Infusion System 9-084-PR1-2-2, www.hospira.com/products/gemstar_painmanagement.aspx, Jan. 28, 2010, pp. 1-2.
Introducing Abbott TQPM (Total Quality Pain Management), Abbott Laboratories, Abbott Park, IL, May 2000, pp. 1-4.
“Infusion Pump”, Wikipedia.org, https://web.archive.org/web/20140703024932/https://en.wikipedia.org/wiki/infusion_pump, as last modified Mar. 27, 2014, pp. 3.
Isaka et al., “Control Strategies for Arterial Blood Pressure Regulation”, IEEE Transactions on Biomedical Engineering, Apr. 1993, vol. 40, No. 4, pp. 353-363.
Johnson et al., “Using BCMA Software to Improve Patient Safety In Veterans Administration Medical Centers”, Journal of Healthcare Information Management, Dec. 6, 2004, vol. 16, No. 1, pp. 46-51.
Kent Displays, “Reflex™ Electronic Skins”, Product Brief 25127B, 2009, pp. 2.
Kent Displays, “Reflex Electronic Skins Engineering Evaluation Kit”, 25136A, Mar. 10, 2009.
Lefkowitz et al., “A Trial of the Use of Bar Code Technology to Restructure a Drug Distribution and Administration System”, Hospital Pharmacy, Mar. 31, 1991, vol. 26, No. 3, pp. 239-242.
Lenssen et al., “Bright Color Electronic Paper Technology and Applications”, IDS '09 Publication EP1-2 (Phillips Research), 2009, pp. 529-532.
Leveson, Nancy, “Medical Devices: The Therac-25”, Appendix A, University of Washington, 1995, pp. 49.
Linkens, D.A. “Computer Control for Patient Care”, Computer Control of Real-Time Processes, IEE Control Engineering Series 41, 1990, Ch. 13, pp. 216-238.
Mako Hill et al., “The Official Ubuntu Book”, Shoeisha Co., Ltd., 1st Edition, Jun. 11, 2007, pp. 115 to 125.
Marshall, et al., “New Microprocessor-Based Insulin Controller”, IEEE Transactions on Biomedical Engineering, Nov. 1983, vol. BME-30, No. 11, pp. 689-695.
Martino et al., “Automation of a Medical Intensive Care Environment with a Flexible Configuration of Computer Systems”, Proceedings of the Annual Symposium on Computer Application in Medical Care, Nov. 5, 1980, vol. 3, pp. 1562-1568.
Matsunaga et al., “On the Use of Machine Learning to Predict the Time and Resources Consumed by Applications”, 2010 10th IEEE/ACM International Conference on Cluster, Cloud and Grid Computing (CCGrid), May 17-20, 2010, pp. 495-504.
MAUSETH et al., “Proposed Clinical Application for Tuning Fuzzy Logic Controller of Artificial Pancreas Utilizing a Personalization Factor”, Journal of Diabetes Science and Technology, Jul. 2010, vol. 4, No. 4, pp. 913-922.
Medfusion™, “Medfusion Syringe Infusion Pump Model 4000”, Operator's Manual, Software Version V1.1, Sep. 2011, pp. 154. http://www.medfusionpump.com/assets/literature/manuals/Operators_Manual_4000_40-5760-51A.pdf.
Metnitz et al., “Computer Assisted Data Analysis in Intensive Care: the ICDEV Project-Development of a Scientific Database System for Intensive Care”, International Journal of Clinical Monitoring and Computing, Aug. 1995, vol. 12, No. 3, pp. 147-159.
Micrel Medical Devices, “MP Daily +” http://web.archive.org/web/20130803235715/http://www.micrelmed.com/index.aspx?productid=9 as archived Aug. 3, 2013 in 1 page.
Moghissi, Etie, MD, FACP, FACE, “Hyperglycemia in Hospitalized Patients”, A Supplement to ACP Hospitalist, Jun. 15, 2008, pp. 32.
Murray, Jr. et al., “Automated Drug Identification System (during surgery)”, IEEE Proceedings of Southeastcon '91, Apr. 7-10, 1991, pp. 265.
Nicholson et al., “Smart' Infusion Apparatus for Computation and Automated Delivery of Loading, Tapering, and Maintenance Infusion Regimens of Lidocaine, Procainamide, and Theophylline”, Proceedings of The Seventh Annual Symposium on Computer Applications in Medical Care, Oct. 1983, pp. 212-213.
Nolan et al., “The P1073 Medical Information Bus Standard: Overview and Benefits for Clinical Users”, 1990, pp. 216-219.
Omnilink Systems, Inc., “Portable Medical Equipment Tracking”, http://www.omnilink.com/portablemedicalequipmenttracking/, Mar. 15, 2015, pp. 2.
O'Shea, Kristen L., “Infusion Management: Working Smarter, Not Harder”, Hospital Pharmacy, Apr. 2013, vol. 48, No. 3, pp. S1-S14.
Package Management in Debian GNU/Linux, Debian GNU/Linux Expert Desktop Use Special, Giutsu-Hyohron Co., Ltd., First Edition, Sep. 25, 2004, pp. 183-185.
Passos et al., “Distributed Software Platform for Automation and Control of General Anaesthesia”, Eighth International Symposium on Parallel and Distributed Computing, ISPDC '09, Jun. 30-Jul. 4, 2009, pp. 8.
Pretty et al., “Hypoglycemia Detection in Critical Care Using Continuous Glucose Monitors: An in Silico Proof of Concept Analysis”, Journal of Diabetes Science and Technology, Jan. 2010, vol. 4, No. 1, pp. 15-24.
Rappoport, Arthur E., “A Hospital Patient and Laboratory machine-Readable Identification System (MRIS) Revisited”, Journal of Medical Systems, Apr. 1984, vol. 8, Nos. 1/2, pp. 133-156.
Ritchie et al., “A Microcomputer Based Controller for Neuromuscular Block During Surgery”, Annals of Biomedical Engineering, Jan. 1985, vol. 13, No. 1, pp. 3-15.
Saager et al., “Computer-Guided Versus Standard Protocol for Insulin Administration in Diabetic Patients Undergoing Cardiac Surgery”, Annual Meeting of the American Society of Critical Care Anesthesiologists, Oct. 13, 2006.
Sanders et al., “The Computer in a Programmable Implantable Medication System (PIMS)”, Proceedings of the Annual Symposium on Computer Application in Medical Care, Nov. 2, 1982, pp. 682-685.
Schilling et al., “Optimizing Outcomes! Error Prevention and Evidence-Based Practice with IV Medications”, A Pro-Ce Publication, Hospira, Inc., Feb. 6, 2012, pp. 56.
Schulze et al., “Advanced Sensors Technology Survey”, Final Report, Feb. 10, 1992, pp. 161.
Scott, et al., “Using Bar-Code Technology to Capture Clinical Intervention Data in a Hospital with a Stand-Alone Pharmacy Computer System”, Mar. 15, 1996, American Journal of Health-System Pharmacy, vol. 53, No. 6, pp. 651-654.
Sebald et al., “Numerical Analysis of a Comprehensive in Silico Subcutaneous Insulin Absorption Compartmental Model”, 31st Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Sep. 2-6, 2009, pp. 3901-3904.
Shabot, M. Michael, “Standardized Acquisition of Bedside Data: The IEEE P1073 Medical Information Bus”, International Journal of Clinical Monitoring and Computing, vol. 6, Sep. 27, 1989, pp. 197-204.
Sheppard, Louis, Ph.D., “Automation of the Infusion of Drugs Using Feedback Control”, Journal of Cardiothoracic and Vascular Anesthesia, Feb. 28, 1989, vol. 3, No. 1, pp. 1-3.
Sheppard, Louis, Ph.D., “Computer Control of the Infusion of Vasoactive Drugs”, Annals of Biomedical Engineering, Jul. 1980, vol. 8, No. 4-6, pp. 431-444.
Sheppard, Louis, Ph.D., “The Application of Computers to the Measurement, Analysis, and Treatment of Patients Following Cardiac Surgical Procedures”, The University of Alabama in Birmingham, Oct. 31, 1977, pp. 297-300.
Sheppard, Louis, Ph.D., “The Computer in the Care of Critically Ill Patients”, Proceedings of the IEEE, Sep. 1979, vol. 67, No. 9, pp. 1300-1306.
“SIGMA SPECTRUM: Operator's Manual”, Oct. 2009, pp. 72. http://static.medonecapital.com/manuals/userManuals/Sigma-Spectrum-Operator-Manual-October-2009.pdf.
Simonsen, Michael Ph.D., POC Testing, New Monitoring Strategies on Fast Growth Paths in European Healthcare Arenas, Biomedical Business & Technology, Jan. 2007, vol. 30, No. 1, pp. 1-36.
Siv-Lee et al., “Implementation of Wireless ‘Intelligent’ Pump IV Infusion Technology in a Not-for-Profit Academic Hospital Setting”, Hospital Pharmacy, Sep. 2007, vol. 42, No. 9, pp. 832-840. http://www.thomasiand.com/hpj4209-832.pdf.
Slack, W.V., “Information Technologies for Transforming Health Care”, https://www.andrew.cmu.edu/course/90-853/medis.dir/otadocs.dir/03ch2.pdf, Ch. 2, 1995, pp. 29-78.
Smith, Joe, “Infusion Pump Informatics”, CatalyzeCare: Transforming Healthcare, as printed May 12, 2011, pp. 2.
Sodder, Lisa, “A Center Keeps Medicine in Right Hands”, Dec. 4, 1999, pp. 1-2.
Stitt, F.W., “The Problem-Oriented Medical Synopsis: a Patient-Centered Clinical Information System”, Proceedings of the Annual Symposium on Computer Application in Medical Care, 1994, pp. 88-92.
Stokowski, Laura A. RN, MS, “Using Technology to Improve Medication Safety in the Newborn Intensive Care Unit”, Advances in Neonatal Care, Dec. 2001, vol. 1, No. 2, pp. 70-83.
Sutton et al., “The Syntax and Semantics of the PROforma Guideline Modeling Language”, Journal of the American Medical Informatics Association, Sep./Oct. 2003, vol. 10, No. 5, pp. 433-443.
Szeinbach et al., “Automated Dispensing Technologies: Effect on Managed Care”, Journal of Managed Care Pharmacy (JMCP), Sep./Oct. 1995, vol. 1, No. 2, pp. 121-127.
Szolovits et al., “Guardian Angel: Patient-Centered Health Information Systems”, Technical Report MIT/LCS/TR-604, Massachusetts Institute of Technology Laboratory for Computer Science, May 1994, pp. 39.
Van Den Berghe, M.D., Ph.D., et al., “Intensive Insulin Therapy in Critically Ill Patients”, The New England Journal of Medicine, Nov. 8, 2001, vol. 345, No. 19, pp. 1359-1367.
Van Den Berghe, M.D., Ph.D., et al., “Intensive Insulin Therapy in the Medical ICU”, The New England Journal of Medicine, Feb. 2, 2006, vol. 354, No. 5, pp. 449-461.
Van Der Maas et al., “Requirements for Medical Modeling Languages”, Journal of the American Medical Informatics Association, Mar./Apr. 2001, vol. 8, No. 2, pp. 146-162.
Villalobos et al., “Computerized System in Intensive Care medicine”, Medical Informatics, vol. 11, No. 3, 1986, pp. 269-275.
Wilkins et al., “A Regular Language: The Annotated Case Report Form”, PPD Inc., PharmaSUG2011—Paper CD18, 2011, pp. 1-9.
Ying et al., “Regulating Mean Arterial Pressure in Postsurgical Cardiac Patients. A Fuzzy Logic System to Control Administration of Sodium Nitroprusside”, IEEE Engineering in Medicine and Biology Magazine, vol. 13, No. 5, Nov.-Dec. 1994, pp. 671-677.
Yue, Ying Kwan, “A Healthcare Failure Mode and Effect Analysis on the Safety of Secondary Infusions”, Thesis, Institute of Biomaterials and Biomedical Engineering, University of Toronto, 2012, pp. 168.
Yurkonis et al., “Computer Simulation of Adaptive Drug Infusion”, IEEE Transactions on Biomedical Engineering, vol. BME-34, No. 8, Aug. 1987, pp. 633-635.
Zakariah et al., “Combination of Biphasic Transmittance Waveform with Blood Procalcitonin Levels for Diagnosis of Sepsis in Acutely Ill Patients”, Critical Care Medicine, 2008, vol. 36, No. 5, pp. 1507-1512.
International Preliminary Report on Patentability and Written Opinion received in PCT Application No. PCT/US2004/037900, dated May 15, 2006 in 5 pages.
International Search Report and Written Opinion received in PCT Application No. PCT/US2004/033409, dated Sep. 13, 2015 in 11 pages.
International Preliminary Report on Patentability and Written Opinion received in PCT Application No. PCT/US2004/033409, dated Apr. 10, 2006 in 7 pages.
“File Verification”, Wikipedia.org, dated Oct. 11, 2011 in 2 pages, https://en.wikipedia.org/w/index.php?title=File_verification&oldid=455048290.
“Software Versioning”, Wikipedia.org, dated Oct. 16, 2011 in 11 pages, https://en.wikipedia.org/w/index.php?title=Software_versioning&oldid=455859110.
Related Publications (1)
Number Date Country
20170274140 A1 Sep 2017 US
Provisional Applications (2)
Number Date Country
60527550 Dec 2003 US
60519646 Nov 2003 US
Divisions (1)
Number Date Country
Parent 10783877 Feb 2004 US
Child 13301518 US
Continuations (1)
Number Date Country
Parent 13301518 Nov 2011 US
Child 15435223 US